BMT TANDEM MEETINGS

Comprehensive Update on Blood and Marrow Transplantation
• Laboratory Research • Clinical Investigations • Patient Care

February 22-26 2017

Orlando
Florida
Sanofi Genzyme is
YOUR PARTNER IN TRANSPLANTATION

We are
COMMITTED
to improving the care of transplant patients

US.PLE.16.12.002
© 2002-2017 sanofi-aventis U.S. LLC.
All rights reserved.

SANOFI GENZYME
Welcome

On behalf of the Organizing Committee, we extend our warm welcome as you arrive for the 2017 BMT Tandem Meetings in Orlando. Our five days of plenary sessions, concurrent scientific and oral abstract sessions, Meet-the-Professor lunches and symposia will present recent progress in basic science, translational research and clinical studies in all areas of blood and marrow transplantation and cellular therapy.

This year we expect more than 3,200 attendees and are proud to have 569 abstracts submitted by authors from more than 25 countries. Registered attendees have the option to view an electronic copy or hard copy of the official supplement to the March 2017 issue of Biology of Blood and Marrow Transplantation containing each of the accepted abstracts presented at the meeting. The abstract supplement also features a review article highlighting one of the scientific sessions.

In keeping with a growing tradition, eleven parallel conferences of specialized sessions will be attended by more than 1,400 transplant nurses, clinical research professionals, BMT pharmacists, BMT center administrators, and advanced practice professionals. We continue to host a Pediatric BMT Program on Thursday that highlights the specific issues of cellular therapy in children and adolescents.

Special thanks to our corporate partners, without whom we would not be able to provide this important international forum for the science and practice of hematopoietic stem cell therapy. They continue to support our meetings through their grants and exhibits and we are truly grateful for their enduring loyalty.

We wish you a productive and stimulating time at the BMT Tandem Meetings and an enjoyable stay in sunny Florida.

Very sincerely,

Marcel R.M. van den Brink, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Program Co-Chair, ASBMT

David I. Marks, MBBS, PhD
University Hospitals Bristol NHS Trust
Bristol, United Kingdom
Program Co-Chair, CIBMTR

Join the conversation on Twitter:
#BMTTandem17
Table of Contents

BMT Tandem Meetings Scientific Organizing Committee ........................................ 1
Target Audience ................................................................................................. 1
Educational Objectives ....................................................................................... 1
Continuing Medical and Professional Education .................................................. 2
  ACCME Accreditation Statement ........................................................................ 2
  AMA Credit Designation Statement ................................................................... 2
  Hours of Participation for Allied Health Professionals ....................................... 2
  CME Certificate ................................................................................................. 2
  Certificate of Attendance ................................................................................... 2
Pharmacist Education ........................................................................................... 3
Nursing Education ................................................................................................ 3
Faculty Disclosure ................................................................................................. 3
General Information
  Abstract Book .................................................................................................... 4
  Attire .................................................................................................................. 4
  2017 BMT Tandem Reception .......................................................................... 4
  Breakfast and Lunch Options ............................................................................. 4
  Business Center ................................................................................................ 4
  Conference Registration Desk .......................................................................... 5
  Emergency Planning ............................................................................................ 5
  Exhibits .............................................................................................................. 5
  Getting Around Orlando .................................................................................... 5
  Internet Access Center and Charging Lounge ................................................ 6
  Lost and Found .................................................................................................. 6
  Meeting Locations .............................................................................................. 6
  Meet-the-Professor Sessions ............................................................................. 7
  Mobile App ........................................................................................................ 8
  Name Badges ...................................................................................................... 8
  Physician Payments Sunshine Act .................................................................. 8
  Posters ............................................................................................................... 8
  Recordings .......................................................................................................... 9
  Research Statistics Consultation ..................................................................... 9
  Speaker Ready Room ......................................................................................... 9
  Wi-Fi .................................................................................................................. 9
Product Theaters ................................................................................................... 10
Corporate Support ................................................................................................. 11
ASBMT Leadership .............................................................................................. 14
CIBMTR Leadership ............................................................................................ 15
ASBMT Travel Grant Recipients .......................................................................... 17
Pre-Conference Agenda

Monday, February 20 ........................................... 18
Tuesday, February 21 ........................................... 18

Conference Agenda

Wednesday, February 22 ........................................ 20
  *Poster Session I* ........................................... 30
Thursday, February 23 ......................................... 31
  *Pediatric BMT Program* .................................. 36
Friday, February 24 ............................................. 47
  *Best Abstracts Session* .................................... 55
  *CIBMTR Awards* .......................................... 56
  *ASBMT Awards* ........................................... 58
  *Mortimer M. Bortin Lecture* ............................ 60
  *E. Donnall Thomas Lecture* .............................. 61
Saturday, February 25 .......................................... 62
  *Poster Session II* .......................................... 73
  *BMT Tandem Meetings Reception* ....................... 73
Sunday, February 26 ............................................ 74

CIBMTR Clinical Research Professionals/
  Data Management Conference ............................ 77
CRP/DM In-Depth Training .................................. 80
BMT CTN Investigators Meeting ............................ 81
BMT CTN Coordinators Meeting ............................ 82
Building a Patient-Centered Outcomes Research
  (PCOR) Collaborative Community ........................ 85
Administrative Directors Conference ..................... 87
HCT Value and Health Economics Session ................ 90
BMT Clinical Education Conference
  (for NPs, PAs, Fellows and Junior Faculty) ............ 91
BMT Pharmacists Conference ............................... 95
Transplant Nursing Conference ............................. 98
2016-2017 ASBMT Committees ............................... 102
ASBMT Special Interest Groups ............................ 105
CIBMTR Working Committees
  *Working Committee Meetings Schedule-at-a-Glance* .... 108
  *Working Committee Leadership and Staff* .............. 110
Invited Faculty .................................................. 113
All Committee Meetings Schedule-at-a-Glance .......... 135
Special Thanks .................................................. 143
Convention Center and Hotel Maps ....................... 146
Abbreviations .................................................... 153
Notes ............................................................. 156
BMT Tandem Meetings
Scientific Organizing Committee

Program Co-Chairs
Marcel R.M. van den Brink, MD, PhD, New York, NY (ASBMT)
David I. Marks, MBBS, PhD, Bristol, UK (CIBMTR)
Bruce R. Blazar, MD, Minneapolis, MN (ASBMT)
Hermann Einsele, MD, Tübingen, Germany (ASBMT)
James L.M. Ferrara, MD, DSc, New York, NY (ASBMT)
Helen E. Heslop, MD, Houston, TX (CIBMTR)
Mary M. Horowitz, MD, MS, Milwaukee, WI (CIBMTR)
Yoshihisa Kodera, MD, PhD, Aichi, Japan (CIBMTR)
Leo Luznik, MD, Baltimore, MD (ASBMT)
Margaret L. MacMillan, MD, MSc, Minneapolis, MN (ASBMT)
Paul J. Martin, MD, Seattle, WA (CIBMTR)
Shinichiro Okamoto, MD, Tokyo, Japan (ASBMT)
Thomas C. Shea, MD, Chapel Hill, NC (CIBMTR)
Kirsten M. Williams, MD, Washington, DC (CIBMTR)
Mei-Jie Zhang, PhD, Milwaukee, WI (CIBMTR)

Target Audience
Health professionals with a clinical interest in blood and marrow transplantation and related investigations, advanced practice professionals, laboratory technicians, clinical research professionals, pharmacists, nurses, data managers, BMT center administrators, and other allied health professionals.

Educational Objectives

• Report on the state of the art in cellular therapy and blood and marrow transplantation.
• Analyze new methods and controversial issues in clinical management strategies for reducing toxicity.
• Assess new basic science information in areas of immunogenetics, molecular biology, stem cell biology, and immunology as it relates to hematopoietic stem cell transplantation in the treatment of hematologic malignancy and solid tumors.
• Review accomplishments of ASBMT, including progress on organizational, societal, and regulatory issues in blood and marrow transplantation.
• Review CIBMTR research accomplishments and set the organization’s scientific agenda for next year.
• Report on contemporary principles in BMT nursing, pharmacy, data management, clinical research analysis, and transplant center administration.
Continuing Medical and Professional Education

The 2017 BMT Tandem Meetings are sponsored by the Medical College of Wisconsin.

ACCME Accreditation Statement
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

AMA Credit Designation Statement
The Medical College of Wisconsin designates this live activity for a maximum of 47.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Professionals
The Medical College of Wisconsin designates this activity for up to 36.0 hours of participation for continuing education for allied health professionals attending the Clinical Research Professionals/Data Management Conference, Clinical Education Conference, BMT CTN Coordinators and Investigators Meetings and Health Economics Session (held during the Administrative Directors Conference).

CME Certificate
Evaluation Forms and a Session Credit Summary will be available on the 2017 BMT Tandem Meetings Home Page to record the number of credits earned. Kiosks are available at the conference to complete evaluations. CME credit will not be issued without completion of the online evaluation. The CME Certificate, indicating sessions attended and credits earned, will be available for download after online evaluation forms have been completed. An electronic copy of this certificate will be filed with the Medical College of Wisconsin. There is a $60 fee for CME Certificates requested 30 days after the conference concludes. Certificates will not be mailed.

Certificate of Attendance
Certificates of Attendance are complimentary if requested during registration or on-site at the conference. There is a $60 fee for Certificates of Attendance requested after the conference.
Pharmacist Education
Syntaxx Communications, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Syntaxx Communications has assigned 12.5 contact hours (1.25 CEUs) of continuing pharmacy education credit for this knowledge- and application-based activity. This two-day live conference will incorporate 13 individual activity sessions that combined will fulfill the 12.5 hours of CE. The target audience for this accredited activity is pharmacists. To receive continuing pharmacy education credit for the Conference, participants must attend the sessions in their entirety and complete the associated program evaluation forms.

Additionally, all US-based pharmacists must supply their National Association of Boards of Pharmacy (NABP) electronic Profile Identification (ePID) number and their birth month and day (MM/DD). No credit can or will be issued without this information. To acquire an NABP ePID, go to http://www.nabp.net and click on CPE Monitor. Universal Activity Numbers: 0299-9999-17-001-L01-P through 0299-9999-17-013-L01-P. For questions or issues related to continuing pharmacy education, please contact Syntaxx Communications: jmarino@syntaxxcomm.com.

Nursing Education
Registered attendees can earn 17.5 CNE if all educational sessions are attended in their entirety.

The Oncology Nursing Society (ONS) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Nurses can earn up to an additional 3 CNE for viewing the poster abstracts on their own time. For every 19 posters viewed, an additional 1 CNE can be earned.

Faculty Disclosure
The 2017 BMT Tandem Meetings are committed to providing unbiased, balanced, and objective educational and scientific programs. In accordance with ACCME guidelines, all planners and speakers are asked to provide disclosures of their relevant financial relationships, which are available online for audience review. The CME provider has a mechanism in place to identify and resolve any conflicts of interest prior to the start of each presentation. Audience members will be asked to assess each presentation for the presence/absence of commercial bias.
General Information

Abstract Book
All accepted abstracts for the BMT Tandem Meetings are published in a supplement to the March 2017 issue of *Biology of Blood and Marrow Transplantation* (Vol. 23, No. 3, Supplement 1). Registered attendees have the option to view an electronic copy or hard copy of the abstract book.

The Abstract Book is supported by **Celgene Corporation**.

Attire
Casual business or resort wear is appropriate for the entire week at all events, including the Saturday evening BMT Tandem Reception at Gaylord Palms. The Convention Center may be cool in the meeting rooms, requiring a light sweater or jacket.

2017 BMT Tandem Reception
Join ASBMT President, Christopher Bredeson, MD, MSc and CIBMTR Chair, Paul J. Martin, MD for an enjoyable evening of conversation, complimentary beverages and cuisine and dancing on Saturday, February 25. The evening will begin on the Coquina Lawn at the Gaylord Palms, then move into Wreckers Nightclub, just off the lawn, for dancing. Tickets are available online and at the Registration Desk until Thursday, February 23 at 5:00 pm, subject to availability.

Breakfast and Lunch Options

**Symposia**
Grab breakfast or lunch in Exhibit Hall F and attend scientific symposia.

**Committee Meetings**
Attend a committee meeting, such as one of the CIBMTR Working Committee meetings (open to all attendees) or another meeting to which you have been invited.

**Meet-the-Professor Lunch Sessions**
Meet-the-Professor sessions will be held Wednesday through Saturday; tickets are $35 and may be purchased at the Conference Registration Desk (subject to availability). Details on page 7.

**BMT Tandem Buffet**
Choose from a selection of continental breakfast and lunch items located in Exhibit Hall F.

Business Center
The Business Center is located on the Mezzanine Level of the Gaylord Palms Convention Center and is open daily from 7:00 am to 7:00 pm.
Conference Registration Desk

The BMT Tandem Meetings Registration Desk is located in the Florida Exhibit Hall Lobby F, Level 1 of the Gaylord Palms Convention Center. On-site Conference Registration Desk hours are:

- Monday, February 20: 5:00 pm – 8:00 pm
- Tuesday, February 21: 7:00 am – 6:00 pm
- Wednesday, February 22: 7:00 am – 6:00 pm
- Thursday, February 23: 7:00 am – 6:00 pm
- Friday, February 24: 7:00 am – 6:00 pm
- Saturday, February 25: 7:00 am – 6:00 pm
- Sunday, February 26: 7:00 am – 1:30 pm

For after-hours technical assistance regarding registration, please contact: bmttandemregistration@conferencedirect.com.

Emergency Planning

In the event of an emergency dial “33” on any in-house phone. When reporting an emergency, be sure to stay calm and be prepared to give the following information:

- Your name
- Exact location where assistance is needed
- Nature of emergency
- The number of people and, if applicable, injuries of those involved.

Local Police, Fire and Ambulance: 911.

Exhibits

Exhibits will be open Wednesday, February 22, through Saturday, February 25, from 7:00 am to 2:00 pm in Exhibit Hall F, Level 1.

Getting Around Orlando

The Gaylord Palms Convention Center is easy to access by car, taxi or Uber.

Car Rental

Avis offers meeting attendees special discounts on a wide selection of vehicles, from one week before to one week after the BMT Tandem Meetings. To reserve a car, contact Avis at (800) 331-1212 and use the Avis Worldwide Discount (AWD) number S012600. Or reserve online and include the discount number in the reservation to receive an e-mail confirmation.

The 2017 BMT Tandem Meetings have partnered with Advantage Rent A Car to provide a 10% discount to our registrants. Advantage has also agreed to waive the Second Driver fee (a savings of an additional $13/per day.) The discount rate will remain available from February 15th.
through March 1st. Meeting registrants can visit www.advantage.com/vehicles to place your reservation or contact Advantage at (800) 777-5500 and use the promo code CD06CB077A to take advantage of the discount.

**Internet Access Center and Charging Lounge**

Meeting attendees are invited to make use of the complimentary Internet Access Center, located on Level 2 in the City Hall Lobby of the Gaylord Palms Convention Center.

Complimentary Wi-Fi access is available in all BMT Tandem Meeting rooms at the Gaylord Palms Convention Center. **Network Name: BMTTANDEM; Password: BMT2017!**

Wi-Fi is available thanks to support from Novartis Pharmaceuticals Corporation.

Meeting attendees are invited to make use of the Charging Lounge with complimentary power strips available to recharge laptop and cell phone batteries, located in the City Hall Lobby of the Gaylord Palms Convention Center.

The Charging Lounge is available thanks to support from Sanofi Genzyme.

**Lost and Found**

Please check at the BMT Tandem Meetings Conference Registration Desk for lost items. After the Meetings, remaining items will be left with the Gaylord Palms Convention Center.

**Meeting Locations**


<table>
<thead>
<tr>
<th>Scientific Plenary Sessions</th>
<th>Florida Hall E – Level 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concurrent Scientific Sessions</td>
<td>Florida Halls C, D and E – Level 1</td>
</tr>
<tr>
<td>Exhibits</td>
<td>Exhibit Hall F – Level 1</td>
</tr>
<tr>
<td>Posters</td>
<td>Florida Hall B – Level 1</td>
</tr>
<tr>
<td>BMT CTN Investigators</td>
<td>Sun B – Level 2</td>
</tr>
<tr>
<td>BMT CTN Coordinators</td>
<td>Sun A – Level 2</td>
</tr>
<tr>
<td>Clinical Research Professionals/Data Managers</td>
<td>Osceola D – Level 2</td>
</tr>
<tr>
<td>Pediatric BMT Program</td>
<td>Osceola C – Level 2</td>
</tr>
</tbody>
</table>
Meet-the-Professor Sessions
Fellows and junior faculty have an opportunity for informal discussion with experts in BMT patient management. Each session will feature a case-based discussion led by internationally renowned authorities. Meet-the-Professor Sessions will be held on Wednesday through Saturday and be capped at a maximum of 25 attendees to keep sessions interactive. Tickets are $35 and may be purchased at the Conference Registration Desk, subject to availability.

Wednesday, February 22
12:15 pm – 1:30 pm
Evolution and History of HCT ........ Room Sun 1
Richard J. O’Reilly, MD and Rainer Storb, MD

Cord Blood Transplant ................. Room Sun 2
Juliet N. Barker, MBBS

Thursday, February 23
12:15 pm – 1:30 pm
Unusual Lymphomas and the Role of Autografting and Allografting ........ Room Sun 1
Timothy S. Fenske, MD, MS

Selecting an Alternative Donor ........ Room Sun 2
Bronwen E. Shaw, MD, PhD

Friday, February 24
12:15 pm – 1:30 pm
All Things HLH ....................... Room Sun 1
Rebecca A. Marsh, MD

Special Considerations in HCT for Patients with Sickle Cell Disease ........ Room Sun 2
Nicolas Novitzky, MD, PhD

Saturday, February 25
12:15 pm – 1:30 pm
How Do I Work-Up and Treat Transplant-Associated Microangiopathy (TAM)? Room Sun 1
Joseph H. Antin, MD

How to Propose a Successful Registry Study with CIBMTR .............. Room Sun 2
Steven M. Devine, MD
Mobile App
Download the official BMT Tandem Meetings app for quick and easy access to the schedule, attendee list, venue information and more! Search for BMT Tandem in your app store, enter bmt2017 for access verification and, after downloading the app, enter the same email address used to register for the meeting for additional features. The app is free for all registered attendees. With Wi-Fi available throughout all BMT Tandem meeting rooms, users can:

- View and search the meeting program schedule
- Vote/participate in interactive sessions
- Complete session evaluations
- Search for speakers
- Check out who is exhibiting and find their booth on a map
- Create a personal schedule
- Message other attendees
- Access other meeting information

The Mobile App is supported by Astellas Pharma US, Inc.

Name Badges
Participant name badges must be displayed for admittance to all BMT Tandem Meetings scientific sessions, exhibits, meals and social events. For security reasons, name badges will be checked for admittance to all events and sessions.

Lost badges will be replaced for a charge of $5.

Physician Payments Sunshine Act
BMT Tandem Meetings and the Medical College of Wisconsin (our CME sponsor) is committed to supporting full compliance with the Physician Payment Sunshine Act and strives toward full transparency with collaborators, governing bodies and our learners. Attendance may be tracked at mealtime sessions and poster sessions to report indirect transfers for value provided by a manufacturer to the Centers of Medicare and Medicaid Services in accordance with the Physician Payments Sunshine Act.

Posters
Two Poster Sessions will be held in Florida Hall B of the Gaylord Palms Convention Center. Session I is Wednesday, February 22 from 6:45 pm to 7:45 pm. Session II is Saturday, February 25 from 6:45 pm to 7:45 pm.
Recordings
Professional recordings are available for most plenary and concurrent scientific sessions, as well as parallel conferences. Each recording will be available in either MP3 or MP4 file format in the weeks following the conclusion of the BMT Tandem Meetings. They will be accessible through the online web program.

All available recordings will be made available to registered attendees for a $15 flat rate. This content is also offered to non-attendees: $25 for each MP3 audio download and MP4 audio with synchronized PowerPoint visuals.

Research Statistics Consultation
CIBMTR PhD biostatisticians are available to provide one-on-one consultation on current and planned research projects. No appointment is necessary between 10:30 am and Noon on Thursday and Friday in Room Sarasota 1, Level 2 to consult on study design, sample size, and power calculations.

Speaker Ready Room
The Speaker Ready Room is located in Tampa 3, Level 2 at the Gaylord Palms Convention Center. The Speaker Ready Room hours are: Monday, February 20, 5:00 pm – 8:00 pm; Tuesday, February 21 through Saturday, February 25, 6:00 am – 6:00 pm; and Sunday, February 26, 6:00 am – 12:30 pm. Other availability is by appointment.

Wi-Fi
Complimentary Wi-Fi access is available in all BMT Tandem Meeting rooms at the Gaylord Palms Convention Center. Network Name: BMTTANDEM; Password: BMT2017!

Wi-Fi is available thanks to support from Novartis Pharmaceuticals Corporation.
Product Theaters

BMT Tandem Meetings registered attendees are invited to participate in Product Theater presentations. These presentations are not sponsored or endorsed by the BMT Tandem Meetings. Product Theater sessions are considered promotional, and continuing education credits will not be offered.

Wednesday, February 22
1:30 pm – 2:30 pm
Kite Pharma Product Theater:
CAR-T Therapy in B-Cell Malignancies

1:30 pm – 2:30 pm
Cerus Corporation Product Theater:
Mitigating Risks of Transfusion-Transmitted Infection and Transfusion-Associated GVHD with Pathogen-Reduced Blood Components

Thursday, February 23
1:30 pm – 2:30 pm
Astellas Product Theater:
Invasive Aspergillosis: Risk Factors, Diagnosis, and Overview of CRESEMB® (isavuconazonium sulfate) Treatment with Case Presentation

Friday, February 24
1:30 pm – 2:30 pm
Jazz Pharmaceuticals Product Theater:
Rising to the Challenge of VOD: Advances in the Treatment of Post HCT Patients

1:30 pm – 2:30 pm
Merck Product Theater:
Importance of Antifungal Prophylaxis

Saturday, February 25
1:30 pm – 2:30 pm
Sanofi Product Theater:
Barriers to HCT: Disparities in Multiple Myeloma

1:30 pm – 2:30 pm
Miltenyi Biotec Product Theater:
Cellular Therapy: Established Strategies and Future Visions
Corporate Support

We are grateful for the support of our corporate partners.

Platinum – $200,000
Astellas Pharma US, Inc.
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Pharmacyclics, LLC
Sanofi Genzyme
Seattle Genetics

Gold – $100,000
Actinium Pharmaceuticals, Inc.
Celgene Corporation
Kite Pharma, Inc.
Merck & Co.
Novartis Pharmaceuticals Corporation

Silver – $50,000
Janssen Biotech, Inc.
Millennium, the Takeda Oncology Co.
Shire

Bronze – $10,000
Cerus Corporation
Chimerix, Inc.
Gilead Sciences, Inc.
HistoGenetics
Karyopharm Therapeutics, Inc.
Miltenyi Biotec, GmbH
Actinium Pharmaceuticals, Inc. – $155,625 an educational grant . . . and support for the Saturday breakfast symposium on “Updates on Hematologic Malignancies: New, Targeted Conditioning Regimens”.

Astellas Pharma US, Inc. – $204,000 an educational grant . . . and support for a Product Theater … Mobile App . . . Pocket Schedule . . . Infection and Immune Reconstitution Working Committee Meeting . . . and partial support for the Wednesday luncheon symposium on “Preventing and Managing Cytomegalovirus and Invasive Fungal Infection after Hematopoietic Stem Cell Transplantation: Key Questions, Expert Answers”.

Celgene Corporation – $173,915 an educational grant . . . and support for the Abstract Book . . . and partial support for the Thursday breakfast symposium on “Autologous Transplant in the Area of Novel Therapy in Myeloma”.

Cerus Corporation – $35,000 support for a Product Theater.

Chimerix, Inc. – $20,000 an educational grant . . . and support of the BMT Pharmacists Conference.

Gilead Sciences, Inc. – $15,000 support for the Graft-Versus-Host Disease Working Committee Meeting … and for the Notepad.

HistoGenetics – $45,000 support for the Registration Tote Bags.

Incyte Corporation – $450,731 an educational grant . . . and support for the Friday breakfast symposium on “Maximizing Patient Outcomes in Myelofibrosis: Stem Cell Transplantation in the JAK Inhibitor Era” . . . and partial support for the Saturday luncheon symposium on “Emerging Approaches to Target the Immunologic Chaos of Graft-Versus-Host Disease”.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. – $87,000 an educational grant . . . and partial support for the Thursday breakfast symposium on “Autologous Transplant in the Area of Novel Therapy in Myeloma”.

Jazz Pharmaceuticals, Inc. – $472,580 an educational grant . . . and support for a Product Theater … and for the Friday luncheon symposium on “Maximizing Outcomes with Allogeneic HCT in AML: Insight on the Impact of Novel Therapy”.

Karyopharm Therapeutics, Inc. – $29,750 an educational grant . . . and partial support for the Thursday breakfast symposium on “Autologous Transplant in the Area of Novel Therapy in Myeloma”.
Kite Pharma, Inc. – $135,000 an educational grant . . . and support for a Product Theater . . . and partial support for the Friday breakfast symposium on “Utilizing CAR T-Cells for Hematologic Malignancies in the Transplant Setting”.

Merck & Co. – $178,915 an educational grant . . . and support for a Product Theater . . . and partial support for the Wednesday luncheon symposium on “Preventing and Managing Cytomegalovirus and Invasive Fungal Infection after Hematopoietic Stem Cell Transplantation: Key Questions, Expert Answers”.

Millennium, the Takeda Oncology Co. – $60,000 an educational grant . . . and partial support for the Thursday breakfast symposium on “Autologous Transplant in the Area of Novel Therapy in Myeloma”.

Miltenyi Biotec, GmbH – $35,000 support for a Product Theater.

Novartis Pharmaceuticals Corporation – $105,000 an educational grant . . . and partial support for the Friday breakfast symposium on “Utilizing CAR T-Cells for Hematologic Malignancies in the Transplant Setting” . . . and support for Wi-Fi in all BMT Tandem Meeting rooms.

Pharmacyclics, LLC – $225,732 an educational grant . . . and partial support for the Saturday luncheon symposium on “Emerging Approaches to Target the Immunologic Chaos of Graft-Versus-Host Disease” . . . and support of the BMT Pharmacists Conference.

Sanofi Genzyme – $320,000 support for the Program Guide . . . support for the Saturday breakfast symposium on “Optimal Use of Stem Cell Mobilization in Patients with Hematologic Malignancies” . . . the Charging Lounge . . . and a Product Theater.

Seattle Genetics, Inc. – $250,000 an educational grant . . . and support for the Thursday luncheon symposium on “Making the Most of New Options in Hodgkin Lymphoma: Autologous Transplant in the Era of Novel Therapeutics”.

Shire – $75,000 an educational grant . . . and partial support for the Wednesday luncheon symposium on “Preventing and Managing Cytomegalovirus and Invasive Fungal Infection after Hematopoietic Stem Cell Transplantation: Key Questions, Expert Answers”.

With increasing demand for transparency regarding commercial supporters for accredited events, our accrediting bodies have asked that we include the amount of all support provided to the 2017 BMT Tandem Meetings as of January 13, 2017. This does not include fees received for promotional exhibits.
ASBMT Leadership
2016-2017

ASBMT Executive Committee

President
Christopher Bredeson, MD, MSc

President-Elect
Krishna V. Komanduri, MD

Vice President
John DiPersio, MD, PhD

Immediate-Past President
Effie W. Petersdorf, MD

Secretary
Juliet N. Barker, MBBS

Treasurer
Corey S. Cutler, MD, MPH

Directors
H. Joachim Deeg, MD
Colleen Delaney, MD
James Gajewski, MD
Margaret L. MacMillan, MD, MSc
Navneet S. Majhail, MD, MS
Joseph McGuirk, DO
Richard A. Nash, MD
Pavan Reddy, MD
Patrick J. Stiff, MD

Editor-in-Chief
Biology of Blood and Marrow Transplantation
Robert Korngold, PhD

Chair, Annual Meeting Scientific Program Committee
Marcel R.M. van den Brink, MD, PhD

Executive Director
Kenneth J. Luurs, MBA, CAE

Executive Office
85 West Algonquin Road, Suite 550
Arlington Heights, IL 60005
Telephone: (847) 427-0224
Fax: (847) 427-9656
Email: mail@asbmt.org
CIBMTR Leadership 2016-2017

CIBMTR Executive Committee

Chair
Paul J. Martin, MD

Chair-Elect
Robert J. Soiffer, MD

Vice-Chair for North America
Paul Carpenter, MD

Vice-Chair for Central and South America
Nelson Hamerschlak, MD, PhD

Vice-Chair for Europe
Charles Craddock, MD, PhD

Vice-Chair for Asia/Australia/Africa
Mahmoud Aljurf, MD, MPH

Patient/Family Representatives
Jeff Haertling
Maureen Beaman, MBA

Donor Center Representative
Jason Gangewere

Collection Center Representative
Yvonne Ybarra

Business Representative
Theresa Franco, BSN, MSN

Chief Scientific Director
Mary M. Horowitz, MD, MS

Executive Director
Jeffrey W. Chell, MD

Associate Scientific Director
Dennis L. Confer, MD

Chief Statistical Director
Mei-Jie Zhang, PhD

Senior Research Advisor
Daniel J. Weisdorf, MD
Senior Scientific Directors
Linda J. Burns, MD
Mary Eapen, MD, MS
Marcelo C. Pasquini, MD, MS
J. Douglas Rizzo, MD, MS
Bronwen E. Shaw, MD, PhD

Scientific Directors
Mukta Arora, MD, MS
Anita D’Souza, MD, MS
Mehdi Hamadani, MD
Parameswaran N. Hari, MD, MS
Stephanie J. Lee, MD, MPH
Navneet S. Majhail, MD, MS
Marcie L. Riches, MD, MS
Wael Saber, MD, MS
Stephen R. Spellman, MBS

Vice President, CIBMTR Minneapolis
Roberta J. King, MPH

CIBMTR Administrator, CIBMTR Milwaukee
Patricia Steinert, PhD, MBA

CIBMTR BMT Tandem Meetings Staff
Meetings Manager
Tia Houseman

Director of Advancement
Sherry Fisher

CIBMTR Program Coordinators
Maira Brey
Maggie Simaytis

CIBMTR is headquartered at two locations:

Milwaukee Campus at the
Medical College of Wisconsin
Clinical Cancer Center
9200 West Wisconsin Avenue, Suite C5500
Milwaukee, WI 53226
Telephone: (414) 805-0700

Minneapolis Campus at the
Be The Match Coordinating Center
500 North 5th Street
Minneapolis, MN 55401
Telephone: (612) 627-5800
The following hematology and oncology Fellows received travel grants from ASBMT to attend the 2017 BMT Tandem Meetings:

Brandon Blue, MD .......................... St. Louis, MO
Michael Chargualaf, PharmD .................. Chapel Hill, NC
Hannah Choe, MD .......................... New York, NY
Coco deKoning, PhD ........................ Utrecht, Netherlands
Najla El Jurdi, MD .......................... Cleveland, OH
Jessica El-Asmar, MD ........................ Cleveland, OH
Narendranath Epperla, MD ................. Milwaukee, WI
Nicholas Gloude, MD ....................... Cincinnati, OH
Brian Greenwell, MD ....................... Atlanta, GA
Ashish Gupta, MBBS, MPH, FAAP ......... Cleveland, OH
Patrick Hagen, MD, MPH ................... Maywood, IL
Mary Christa Krupski, DO ................. Cincinnati, OH
Hannah Major-Monfried .................. New York, NY
Samip Master, MBBS ...................... Shreveport, LA
Regina Myers, MD ....................... Philadelphia, PA
Ioannis Politikos, MD ...................... New York, NY
Praveen Ramakrishnan Geethakumari, MD ................. Philadelphia, PA
Tahereh Rostami, MD ..................... Tehran, Iran
Seth Rotz, MD ............................. Cincinnati, OH
Lyndsey Runaas, MD ...................... Ypsilanti, MI
Mithun Shah, MD, PhD .................. Houston, TX
Akshay Sharma, MBBS .................. Memphis, TN
Tamna Wangjam, MD .................... San Antonio, TX
Pre-Conference
Monday, February 20

MONDAY CONVENTION SERVICES:

5:00 pm – 8:00 pm
Speaker Ready Room
Tampa 3

5:00 pm – 8:00 pm
Registration Open
Exhibit Hall Lobby

MONDAY COMMITTEE MEETINGS:
By Invitation

7:00 am – 5:00 pm
FACT Standards Kick-Off Meeting
Emerald 1

Tuesday, February 21

TUESDAY CONVENTION SERVICES:

6:00 am – 6:00 pm
Speaker Ready Room
Tampa 3

7:00 am – 6:00 pm
Internet Access Center and Charging Lounge
City Hall Lobby

7:00 am – 6:00 pm
Registration Open
Exhibit Hall Lobby

TUESDAY EXHIBITS:
10:00 am – 5:00 pm
Exhibit Move-In
Exhibit Hall F
TUESDAY COMMITTEE MEETINGS:
By Invitation

8:30 am – 5:00 pm
BMT CTN Steering Committee Meeting
Osceola C

6:00 pm – 10:00 pm
FACT Board of Directors Meeting
Daytona 1-2

TUESDAY PERIPHERAL CONFERENCES:

7:00 am – 5:00 pm
FACT Cellular Therapy Inspection and Accreditation Workshop Applicant Track
Tallahassee 1-3
Separate Registration Required. Contact FACT at fact@unmc.edu or call (402) 559-1950.

7:00 am – 5:00 pm
FACT Cellular Therapy Inspection and Accreditation Workshop Inspector Track
Sanibel 1-3
Separate Registration Required. Contact FACT at fact@unmc.edu or call (402) 559-1950.

7:30 am – 6:30 pm
Clinical Research Professionals/Data Management (CRP/DM) Conference
Osceola D
See page 77 for agenda

8:00 am – Noon
FACT Cellular Therapy Leadership Course 101
Miami 1
Separate Registration Required. Contact FACT at fact@unmc.edu or call (402) 559-1950.

1:00 pm – 5:00 pm
FACT Advanced Cellular Therapy Leadership Course 201
Miami 1
Separate Registration Required. Contact FACT at fact@unmc.edu or call (402) 559-1950.
Wednesday, February 22

**WEDNESDAY CONVENTION SERVICES:**

- **6:00 am – 6:00 pm**
  Speaker Ready Room
  Tampa 3

- **7:00 am – 6:00 pm**
  Internet Access Center and Charging Lounge
  City Hall Lobby

- **7:00 am – 6:00 pm**
  Registration Open
  Exhibit Hall Lobby

**WEDNESDAY EXHIBITS:**

- **7:00 am – 2:00 pm**
  Exhibits Open
  Exhibit Hall F

- **9:00 am – 5:00 pm**
  BMT Tandem Poster Session I
  Set-Up and Preview
  Florida Hall B

- **6:45 pm – 7:45 pm**
  BMT Tandem Poster Session I – Meet the Authors
  Florida Hall B

**WEDNESDAY COMMITTEE MEETINGS:**

Open to All Attendees

- **7:00 am – 8:30 am**
  Radiation Injury Treatment Network (RITN) Annual Update
  Sanibel 1-3

- **7:00 am – 5:00 pm**
  FACT ASBMT Quality Boot Camp
  Miami 1-3
  Separate Registration Required. Contact FACT at fact@unmc.edu or call (402) 559-1950.

- **10:00 am – 11:00 am**
  ASBMT Introduction/Orientation for Fellows-in-Training
  Sanibel 1-3
WEDNESDAY COMMITTEE MEETINGS:
Open to All Attendees

12:15 pm – 2:15 pm
CIBMTR Working Committee Meeting:
Plasma Cell Disorders and Adult Solid Tumors
Naples 1-3

12:15 pm – 4:45 pm
CIBMTR Working Committee Meeting:
Immunobiology
Osceola 1-3

2:45 pm – 4:45 pm
CIBMTR Working Committee Meeting:
Late Effects and Quality of Life
Naples 1-3

2:45 pm – 4:45 pm
CIBMTR Working Committee Meeting:
Primary Immune Deficiencies, Inborn Errors of Metabolism and Other Non-Malignant Marrow Disorders
Osceola 4-6

5:00 pm – 6:30 pm
Cell Therapy Registry Pilot Center Update
St. George #108

5:00 pm – 7:00 pm
FACT Global Affairs:
Special Session for International Delegates
Captiva 1-2

WEDNESDAY COMMITTEE MEETINGS:
By Invitation

7:00 am – 8:00 am
ASBMT Committee on Cellular Therapy
St. George #112

7:00 am – 8:30 am
Transplant Late Effects in Children (TLEC) Investigators Meeting
Orange Blossom Ballroom

7:30 am – 8:30 am
ASBMT Committee on RFI
St. George #104
WEDNESDAY COMMITTEE MEETINGS:
By Invitation

10:30 am – Noon
FACT Clinical Outcomes Committee Meeting
Daytona 1-2

Noon – 1:00 pm
FACT Consultants Meeting
Daytona 1-2

12:15 pm – 4:15 pm
CIBMTR Advisory Committee Meeting
Osceola C

1:00 – 2:00 pm
FACT Consultants Board of Directors Meeting
Daytona 1-2

5:00 pm – 6:30 pm
CRP/DM Conference Planning Meeting
for 2018
Sun 2

6:45 pm – 7:45 pm
ASBMT Committee on Practice Guidelines
St. George #112

6:45 pm – 8:00 pm
FACT Web Oversight Committee Meeting
Daytona 1-2

6:45 pm – 8:45 pm
BMT CTN Myeloma Intergroup Meeting
Tallahassee 1-3

7:00 pm – 9:00 pm
NMDP Transplant Center Networking
Reception – Open to NMDP/Be The Match
Network Transplant Centers Only
St. Augustine: Castillo de San Marcos Fort – Lower Level
**WEDNESDAY PERIPHERAL CONFERENCES:**

7:00 am – 8:15 am  
**BMT CTN Investigators Meeting**  
Sun B  
See page 81 for agenda

7:00 am – 5:30 pm  
**Beyond Fundamentals of HCT**  
Tallahassee 1-3  
Separate Registration Required.

8:00 am – 10:00 am  
**Introduction to the FACT Accreditation Portal**  
Daytona 1-2  
Separate Registration Required. Contact FACT at fact@unmc.edu or call (402) 559-1950.

8:30 am – 4:30 pm  
**BMT CTN Coordinators Meeting**  
Sun A  
See page 82 for agenda

8:30 am – 4:45 pm  
**Clinical Research Professionals/ Data Management Conference**  
Osceola B  
See page 78 for agenda

2:30 pm – 4:30 pm  
**Introduction to the FACT Accreditation Portal**  
Daytona 1-2  
Separate Registration Required. Contact FACT at fact@unmc.edu or call (402) 559-1950.
7:00 am – 8:15 am
BMT CTN Investigators Meeting
The BMT CTN Investigators Meeting is for investigators and clinic and research staff involved in BMT CTN studies. Physicians at centers interested in becoming involved in the BMT CTN are also welcome to attend.

Sun B

7:00 am – 7:10 am
Welcome Address
Steven M. Devine, MD

7:10 am – 7:30 am
BMT CTN 0702 STaMINA Primary Results
Marcelo C. Pasquini, MD, MS

7:30 am – 7:45 am
BMT CTN 1506 FLT3+ AML Maintenance Therapy
Yi-Bin Chen, MD

7:45 am – 8:00 am
BMT CTN 0201 BM Versus PB Five-Year Follow-Up Results
Stephanie J. Lee, MD, MPH

8:00 am – 8:15 am
Risk Stratified Trials in GVHD
Amin M. Alousi, MD

8:15 am – 8:30 am
Opening Session:
Welcome to the 2017 BMT Tandem Meetings
Florida Hall E

Conference Co-Chairs:
Marcel R.M. van den Brink, MD, PhD and David I. Marks, MBBS, PhD
SCIENTIFIC PLENARY SESSION

8:30 am – 10:00 am
The Future of BMT “Immunotherapy of Cancer”
Florida Hall E
Chair: Ann M. Leen, PhD

- Personalized Cancer Vaccines for Hematologic Malignancies
  David E. Avigan, MD

- Adoptively Transferred Tumor-Specific T-Cells
  Ann M. Leen, PhD

- Targeting Personal Neoantigens through Cancer Vaccines
  Catherine Wu, MD

10:00 am – 10:30 am – BMT Tandem Morning Break

CONCURRENT SCIENTIFIC SESSIONS

10:30 am – Noon
NMDP Session: The Value of Emerging Cellular Therapies
Florida Hall E
Co-Chairs: Michael Boo, JD and Kent H. Walters, MBA

- Industry Perspective on Valuing New Technologies
  Laurel Todd, MBA

- Determining the Value of Cell Therapies through Health Services Research
  Linda J. Burns, MD

- Cell Therapy Reimbursement: The Good, the Bad, the Ugly
  Stephanie A. Farnia, MPH

10:30 am – Noon
Long-Term Survivorship after HCT: Roadmap for Research and Care
Florida Hall D
Chair: Minoo Battiwalla, MD, MS

- The Potentially Lethal Late Effects
  Minoo Battiwalla, MD, MS

- Patient-Reported Concerns: Psychological and Social Impact
  André Tichelli, MD

- HCT Survivorship: Research Methods and Care Delivery
  Navneet S. Majhail, MD, MS
10:30 am – Noon
Primer on New Multiscale Biology/Immunology for Transplanters
Florida Hall C
Chair: Robert Negrin, MD

Modeling Organism-Wide Immunity in Health and Cancer
Matthew Spitzer, PhD

Immunobiology of Tolerance Induction with Low-Dose Interleukin-2
John Koreth, MBBS, DPhil

High Throughput Sequencing to Track T-Cell Cloning Units of Disease in Hematopoietic Cell Transplantation
Everett Meyer, MD, PhD

LUNCH OPTIONS

Noon – 1:15 pm – BMT Tandem Buffet
Exhibit Hall F

BMT TANDEM LUNCHEON SYMPOSIUM:

12:30 pm – 1:30 pm
Preventing and Managing Cytomegalovirus and Invasive Fungal Infection after Hematopoietic Stem Cell Transplantation: Key Questions, Expert Answers
Florida Hall E

Introduction and Key Questions on the Modern Prevention and Treatment of CMV and Invasive Fungal Infection in the HCT Setting
Dimitrios P. Kontoyiannis, MD

Advances in Treatment and Prevention of CMV Disease in HCT Recipients
Michael J. Boeckh, MD

Invasive Fungal Infections in HCT Recipients: Evidence-Based Perspectives on Prevention and Treatment
Dimitrios P. Kontoyiannis, MD

Q&A and Concluding Remarks
Dimitrios P. Kontoyiannis, MD

This activity is supported by independent educational grants from Astellas, Merck & Co., Inc., and Shire.
MEET-THE-PROFESSOR SESSIONS:
Meet-the-Professor luncheon tickets are $35, available for purchase at the BMT Tandem Meetings Registration Desk and subject to availability.

12:15 pm – 1:30 pm
Evolution and History of HCT
Sun 1
Richard J. O'Reilly, MD and Rainer Storb, MD

12:15 pm – 1:30 pm
Cord Blood Transplant
Sun 2
Juliet N. Barker, MBBS

CONCURRENT ORAL ABSTRACT SESSIONS

4:45 pm – 6:45 pm
Oral Abstracts – Session A:
Late Effects, Supportive Care and Quality of Life
Florida Hall E
Moderators: John R. Wingard, MD and Linda J. Burns, MD

Inpatient Integrated Palliative and Transplant Care Improves Caregiver Outcomes of Patients Hospitalized for Hematopoietic Stem Cell Transplantation
Areej R. El-Jawahri, MD

PROMIS and SF36 Patient Reported Outcome Scores are Strongly Correlated in Transplant Survivors
Bronwen E. Shaw, MD, PhD

Association of Socioeconomic Status with Chronic Graft-Versus-Host Disease Outcomes
Betty Ky Hamilton, MD

Risks of New Myeloid Neoplasms after Autologous Transplant for Plasma Cell Myeloma and Lymphomas: Effects of Drug and Ionizing Radiation Exposures
Shabrukh K. Hashmi, MD, MPH

Patient-Reported Outcomes Associated with Chronic GVHD
Stephanie J. Lee, MD, MPH
Long-Term Outcomes Among Two-Year Survivors of Autologous Hematopoietic Cell Transplant for Hodgkin and Diffuse Large B-Cell Lymphoma
Regina Myers, MD

Modifiable Barriers to Adherence to Recommended Health Care Guidelines in Hematopoietic Cell Transplantation Long-Term Survivors
Karen L. Syrjala, PhD

Correlates of Patient and Family Caregiver Anxiety and Depression Symptoms Prior to Allogeneic Hematopoietic Cell Transplantation
Donna M. Poslusny, PhD

4:45 pm – 6:45 pm
Oral Abstracts – Session B:
Leukemia and Infection
Florida Hall D
Moderators: Navneet S. Majhail, MD, MS and John A. Snowden, MD

Human Rhinovirus Infections in Hematopoietic Cell Transplant Recipients: Factors Determining Progression to Lower Tract Disease
Alpana Waghmare, MD

Early Post-Transplant Viral Infections and the Incidence of Acute and Chronic Noninfectious Pulmonary Complications following Hematopoietic Stem Cell Transplantation
Xiaofeng Zhou, PhD

ABO Mismatching and Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia – a Report from the ALWP of the EBMT
Bipin N. Savani, MD

Outcomes of Allogeneic Hematopoietic Cell Transplantation for AML with Complex Karyotypes: A Retrospective Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and MD Anderson Cancer Center
Stefan O. Ciurea, MD
Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Jeffrey E. Lancet, MD

Survival Outcomes Based on Treatment Modality in Acute Lymphoblastic Leukemia: NCDB Analysis

Samip Master, MD

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients

Mithun Vinod Shah, MD, PhD

Infusion of Donor Lymphocytes Specifically Directed to Multiple Tumor Antigens for the Treatment of High-Risk Patients after HCT

Kirsten M. Williams, MD

4:45 pm – 6:45 pm
Oral Abstracts – Session C: Lymphoma and Myeloma and Clinical Cellular Therapy
Florida Hall C
Moderators: Hillard M. Lazarus, MD and Thomas C. Shea, MD

Outcomes in Hodgkin Lymphoma Patients following Allogeneic Transplant after Post-Autologous Transplant Consolidation Therapy with Brentuximab Vedotin: Results of an Exploratory Analysis in the AETHERA Trial

Amanda Cashen, MD

Autologous Transplantation is Associated with Improved Overall Survival in Follicular Lymphoma Patients Experiencing Early Therapy Failure after Frontline Chemo-Immunotherapy: A National Lymphocare Study & CIBMTR Analysis

Carla Casulo

Rituximab Versus Non-Rituximab Containing Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in B-Cell Non-Hodgkin Lymphomas: A CIBMTR Analysis

Narendranath Epperla, MD
Post-Relapse Survival in Lymphoma Patients after Experiencing Therapy Failure following an Allogeneic Hematopoietic Cell Transplantation
Narendranath Epperla, MD

Allogeneic Hematopoietic Cell Transplantation for Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A CIBMTR Analysis
Abraham S. Kanate, MD

Adoptive Transfer of Multi-Tumor Antigen Specific T-Cells as Treatment for Patients with Multiple Myeloma
Premal Lulla, MD

Safety and Efficacy of Donor T-Cells Engineered with Herpes Simplex Virus Thymidine-Kinase Suicide Gene Given after T-Cell Depleted Haploidentical Hematopoietic Transplantation: Results of a 14-Year Follow-Up in 45 Patients
Fabio Ciceri, MD

Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor-T-Cells in Patients with B-Cell Non-Hodgkin Lymphoma: Reversal of Toxicity from Tonic Signaling
Carlos A. Ramos, MD

BMT TANDEM POSTER SESSION I

6:45 pm – 7:45 pm
BMT Tandem Poster Session I – Meet the Authors
Florida Hall B

Session I Posters will remain for viewing until 5:00 pm on Thursday.
THURSDAY CONVENTION SERVICES:

6:00 am – 6:00 pm
Speaker Ready Room
Tampa 3

7:00 am – 6:00 pm
Internet Access Center and Charging Lounge
City Hall Lobby

7:00 am – 6:00 pm
Registration Open
Exhibit Hall Lobby F

THURSDAY EXHIBITS:

7:00 am – 2:00 pm
Exhibits Open
Exhibit Hall F

9:00 am – 5:00 pm
BMT Tandem Poster Session I Viewing
Florida Hall B
Session I Posters must be removed by 6:00 pm on Thursday.

6:15 pm – 7:15 pm
Welcome Reception
Exhibit Hall F
Kick off the 2017 BMT Tandem Meetings by attending the Welcome Reception in Exhibit Hall F. Enjoy complimentary appetizers and beverages as you network with colleagues and our industry partners.

THURSDAY COMMITTEE MEETINGS:

Open to All Attendees

7:00 am – 8:15 am
Orientation to CIBMTR/BMT CTN
Naples 1-3

10:30 am – Noon
Statistical Consulting with CIBMTR PhD Biostatisticians
Sarasota 1
THURSDAY COMMITTEE MEETINGS:
Open to All Attendees

12:15 pm – 2:15 pm
CIBMTR Working Committee Meeting:
Acute Leukemia
Osceola 4-6

12:15 pm – 2:15 pm
CIBMTR Working Committee Meeting:
Autoimmune Diseases and Cellular Therapies
Osceola 1-3

1:00 pm – 3:30 pm
International Data Managers Open Forum
St. George #108

2:45 pm – 4:45 pm
CIBMTR Working Committee Meeting:
Graft Sources and Manipulation
Osceola 4-6

2:45 pm – 4:45 pm
CIBMTR Working Committee Meeting:
Lymphoma
Osceola 1-3

THURSDAY COMMITTEE MEETINGS:
By Invitation

7:00 am – 8:30 am
ASBMT Committee on Education
St. George #104

7:00 am – 8:30 am
RCI BMT Clinical Trials Advisory Committee (CTAC) Meeting
Orange Blossom Ballroom

7:30 am – 8:30 am
ASBMT Palliative Care Special Interest Group
St. George #112

8:30 am – 10:00 am
BMT CTN Coordinators and Investigators Planning Meeting for 2018
Sun 1
THURSDAY COMMITTEE MEETINGS:
By Invitation

9:00 am – 10:30 am
FACT CIBMTR Data Audit Meeting
Daytona 1-2

11:00 am – Noon
FACT CAR T-Cell Task Force Meeting
Daytona 1-2

Noon – 1:00 pm
FACT Regenerative Medicine Task Force Meeting
Daytona 1-2

Noon – 1:30 pm
ASBMT Past President’s Luncheon
St. George #112

12:15 pm – 1:15 pm
ASBMT Committee on Quality Outcomes
Emerald 1

12:30 pm – 2:15 pm
ASBMT Survivorship Research and Special
Interest Group Meeting
Orange Blossom Ballroom

1:00 pm – 4:30 pm
BMT Data Standards and Interoperability
Sun 4-6

1:15 pm – 2:15 pm
ASBMT Sub-Committee on Informatics
Emerald 1

1:30 pm – 3:00 pm
BBMT Editorial Board Meeting
St. George #106

2:00 pm – 3:00 pm
ASBMT Choosing Wisely Task Force
Emerald 6

2:45 pm – 4:45 pm
Patient-Centered Outcomes Research Institute
Survivorship Care Plan (13-SCP) Study Meeting
Orange Blossom Ballroom

4:30 pm – 5:30 pm
ASBMT Corporate Council Reception
Emerald Bay Plaza: Wedding Pavilion
THURSDAY COMMITTEE MEETINGS:
By Invitation

4:45 pm – 6:15 pm
CIBMTR Consumer Advocacy Committee Meeting
Emerald 6

6:15 pm – 7:00 pm
PBMTC Business Meeting and Reception
Osceola A

THURSDAY PERIPHERAL CONFERENCES:

8:30 am – 5:30 pm
Beyond Fundamentals of HCT
Tallahassee 1-3
Separate Registration Required.

8:30 am – 5:15 pm
Transplant Nursing Conference
Osceola D
See page 99 for agenda

8:30 am – 6:00 pm
Administrative Directors Conference
Sun A
See page 87 for agenda

8:30 am – 7:00 pm
Pediatric BMT Program
Osceola AB
See page 36 for agenda

9:00 am – 3:30 pm
In-Depth Training for Clinical Research Professionals/Data Management
Sanibel 1-3
See page 80 for agenda

1:00 pm – 3:00 pm and 3:00 pm – 5:00 pm
Open to All Attendees
Introduction to the FACT Accreditation Portal Day Two
Daytona 1-2
Separate Registration Required. Contact FACT at fact@unmc.edu or call (402) 559-1950.
BREAKFAST OPTIONS

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

BMT TANDEM BREAKFAST SYMPOSIUM:

7:00 am – 8:00 am
Autologous Transplants in the Area of Novel Therapy in Myeloma
Florida Hall E

Welcome and Introduction
Kenneth C. Anderson, MD

The Impact of Novel Therapies on Autologous HCT in Myeloma
Kenneth C. Anderson, MD

Selecting Optimal Treatment in Post-Transplant Relapsed Disease
Shaji Kumar, MD

Symposium Summary and Audience Q&A
Panel

This activity is supported by educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics and Takeda Oncology.
Pediatric BMT Program

The Pediatric BMT Program, run in conjunction with the Pediatric Blood and Marrow Transplant Consortium (PBMTC), is a meeting for physicians, advanced practitioners, nurses, pharmacists, and other staff involved in caring for children undergoing BMT to learn about cutting-edge science and state-of-the-art advances in treatment related to these pediatric patients and the diseases for which they are being treated.

The Medical College of Wisconsin designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Thursday, February 23

Osceola AB

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

8:30 am – 10:00 am
Faith-Based Practice:
Rare Complications Post-Transplant
Osceola C
Chair: Rebecca A. Marsh, MD

Chimerism
  Rebecca A. Marsh, MD

Cytopenias
  Elie Haddad, MD, PhD

TMA after Stem Cell Transplantation:
Crossroad between Our Beliefs and Science
  Sonata Jodele, MD

10:00 am – 10:30 am – Break
CONCURRENT PEDIATRIC SESSIONS

10:30 am – Noon
My Sister’s Keeper – Pediatric Donor Outcomes
Osceola C
Chair: Michael A. Pulsipher, MD

New Insights into Medical Aspects of the Pediatric Donor Experience
Michael A. Pulsipher, MD

Insights into the Pediatric Bone Marrow Donor Experience by Studying Quality of Life Measures
Galen E. Switzer, PhD

How Can Quality of Life Studies in Siblings of Children with Cancer Inform Our Understanding of Sibling Donor Quality of Life?
Cynthia A. Gerhardt, PhD

10:30 am – Noon
New Kids on the Block – Potential New Targetable Pathways
Osceola A
Chair: Alex Huang, MD, PhD

New Roles for Notch Ligands and Fibroblastic Stromal Cells in GVHD
Ivan Maillard, MD, PhD

Cdk5 in Allogeneic T-Cell Activation
John Letterio, MD

IL-27, a Cytokine to Enhance Treg Function to Treat GVHD
Booki Min, PhD

Noon – 12:15 pm – Pediatric BMT Quick Lunch Buffet
Dr. John Wagner is the ninth recipient of the Lifetime Achievement Award from the Pediatric Blood and Marrow Transplant Consortium (PBMTC). Dr. Wagner is being recognized for a career that exemplifies the mission of the PBMTC to support research and education to improve the availability, safety and efficacy of hematopoietic cell transplantation and other cellular therapeutics for children and adolescents.

Dr. Wagner is the Executive Medical Director for the BMT Program at the University of Minnesota Masonic Children’s Hospital and a Professor of Pediatrics at the University of Minnesota Medical School. He is internationally recognized as an expert in the field of stem cells and umbilical cord blood transplantation. He was the first to use umbilical cord blood to treat a child with leukemia in 1990. Dr. Wagner’s research has focused on the development of new treatment approaches for life-threatening diseases for which conventional treatments are unsatisfactory. He is recognized for pioneering the use of double umbilical cord blood transplantation in adults and embryo selection to insure an HLA-matched, healthy child (‘savior sibling’) for another child in need of transplant. He is a leader in the use of regulatory T-Cells to prevent rejection and Graft-Versus-Host Disease, expanded blood-forming stem cells to speed blood and marrow recovery, novel conditioning regimens to dramatically increase the chance of cure of patients with Fanconi anemia and bone marrow derived stem cells to repair the skin in severely affected children with Epidermolysis Bullosa. In addition to being a world-class researcher, physician, author and advisor, Dr. Wagner has made tremendous contributions to medical research by mentoring scientists and physicians who have become leaders in the field.
CONCURRENT PEDIATRIC SESSIONS

1:30 pm – 3:00 pm
Aplastic Anemia – Innovative Approaches
Osceola C
Chair: Andrew C. Dietz, MD, MSCR

- Alternative Treatment with Eltrombopag and Immunosuppression
  Danielle Townsley, MD, MSc

- Serotherapy in BMT for Severe Aplastic Anemia
  Paul Veys, MBBS

- Evolving Transplant Strategies in Severe Aplastic Anemia
  Andrew C. Dietz, MD, MSCR

1:30 pm – 3:00 pm
TMI: Too Much Inflammation
Osceola A
Chair: Carl Allen, MD

- HLH – New Definitions and New Therapies
  Carl Allen, MD

- Obesity and Inflammation in HCT
  Lucie Turcotte, MD

- Cytokine Release Syndrome in Cell Therapy
  David T. Teachey, MD

3:00 pm – 3:15 pm – Break

3:15 pm – 4:15 pm
International Session:
Check Please – Financial Aspects of Cellular Therapy
Osceola C
Chair: Margaret L. MacMillan, MD, MSc

- Canadian Perspective
  Christopher Bredeson, MD, MSc

- U.S. Perspective
  Stephanie A. Farnia, MPH

4:15 pm – 6:15 pm
Best Pediatric Abstracts
Osceola C
Moderators: Carrie L. Kitko, MD and Terry Fry, MD

- Augmentation of Allogenic Cord Blood Transplantation for Inherited Metabolic Diseases with CB-Derived Intrathecal Cellular Therapy, Duoc-01
  Jessica Sun, MD
Genotype, Phenotype and T-Cell Counts at One Year Predict Survival and Long-Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency – the Primary Immune Deficiency Treatment Consortium

Elie Haddad

A Prospective Phase 2 Clinical Trial of KIR Mismatched Unrelated Donor Transplantation for Children and Young Adults with High-Risk AML: A Report of Children’s Oncology Group AAML05P1 Study

Stella M. Davies, MBBS, PhD

Donor Lymphocyte Infusion with Methotrexate to Speed Immune Recovery after CD34-Selected, T-Cell Depleted Haploidentical Donor Transplantation in Children

Andrew L. Gilman, MD

Radiation-Free Salvage Haploidentical HCT with Post-Tx Cy after Rejection/Graft Failure in Children with Non-Malignant Disorders

Michael H. Albert, MD

ROR1-Specific Chimeric Antigen Receptor NK Cell Immunotherapy for High-Risk Neuroblastomas and Sarcomas

Mitchell S. Cairo

CD38 Bright CD8+ TEM Cells Detected Prior to Acute GVHD are Activated, Cytotoxic, Proliferating, Trafficking Cells which are Not Viral Specific

Pooja Khandelwal, MD

Haematopoietic Cell Transplant in Pediatric Acute Myeloid Leukemia after Similar Upfront Therapy with AML-Nopho; A Comparison of Conditioning Regimens

Birgitta Versluys, MD

6:15 pm – 7:00 pm
PBMTC Business Meeting and Reception
Osceola A
Thursday, February 23

SCIENTIFIC PLENARY SESSION

8:30 am – 10:00 am
Aging – Treating the Older Patient
Florida Hall E
Chair: Andrew S. Artz, MD, MS

- The Biology of Frailty and Age-Related Vulnerability to Adverse Health Outcomes
  Jeremy Walston, MD

- The Older Myeloma Patient: Evaluating Aging and Understanding Fitness for Autografting
  Ashley Rosko, MD

- The Older AML Patient: Candidacy and Optimization for Allogeneic Transplant
  Andrew S. Artz, MD, MS

10:00 am – 10:30 am – Break

CONCURRENT SCIENTIFIC SESSIONS

10:30 am – Noon
HaploBMT: A Primer for the Novice and an Update for the Experienced
Florida Hall E
Chair: Leo Luznik, MD

- The Biology of PTCy: How it Allows Us to Cross the HLA Barrier
  Christopher G. Kanakry, MD

- Choosing a Donor Versus Choosing a Regimen – What Do We Know and What Do We Need to Know?
  Richard J. Jones, MD

- Relapse after HaploBMT
  Luca Vago, MD, PhD
10:30 am – Noon
Challenges to BMT in Older Patients: Myeloma, Lymphoma/CLL
Florida Hall D
Chair: Hermann Einsele, MD

Impact of Age and Disease Risk on Treatment Decisions in MDS
H. Joachim Deeg, MD

Is Stem Cell Transplantation Still the Preferred Therapeutic Option for Eligible Patients with Multiple Myeloma?
Hermann Einsele, MD

An Approach to Defining High-Risk Chronic Lymphocytic Leukemia Justifying Allogeneic Transplantation in the Era of Targeted Therapies
Peter Dreger, MD, PhD

10:30 am – Noon
HCT in Autoimmune Diseases
Florida Hall C
Chair: John A. Snowden, MD

Autologous HCT in Multiple Sclerosis
John A. Snowden, MD

Autologous HCT in Connective Tissue Diseases: Clinical Results and Mechanisms
Tobias Alexander, MD

Autologous HCT in Inflammatory Bowel Diseases
Montserrat Rovira, MD, PhD

LUNCH OPTIONS

Noon – 1:15 pm – BMT Tandem Buffet
Exhibit Hall F
Refer to page 4 for a variety of lunch options.
MEET-THE-PROFESSOR SESSIONS:
Meet-the-Professor luncheon tickets are $35, available for purchase at the BMT Tandem Meetings Registration Desk and subject to availability.

12:15 pm – 1:30 pm
Unusual Lymphomas and the Role of Autografting and Allografting
Sun 1
Timothy S. Fenske, MD, MS

12:15 pm – 1:30 pm
Selecting an Alternative Donor
Sun 2
Bronwen E. Shaw, MD, PhD

BMT TANDEM LUNCHEON SYMPOSIUM:
12:30 pm – 1:30 pm
Making the Most of New Options in Hodgkin Lymphoma: Autologous Transplant in the Era of Novel Therapeutics
Florida Hall E

Welcome and Introductions
Anas Younes, MD

Autologous Transplant, Novel Therapies and the Current Hodgkin Lymphoma Paradigm
Robert Chen, MD

A Practical Look at Integrating New Therapy in the Post-HCT Setting
Anas Younes, MD

Key Takeaways and Audience Q&A
Anas Younes, MD and Robert Chen, MD

This activity is supported by an educational grant from Seattle Genetics.
CONCURRENT ORAL ABSTRACT SESSIONS

4:45 pm – 6:15 pm
Oral Abstracts – Session D: Clinical Cellular Therapy, Graft Processing and Immune Reconstitution
Florida Hall E
Moderators: Helen E. Heslop, MD and John F. DiPersio, MD, PhD

TCRβ Sequencing Demonstrates Polyclonality and Persistence of Virus-Specific T-Cell Therapy
Michael Daniel Keller

Stem Cell-Like Memory T-Cells are a Principal Source for Rapid Repopulation of Immunodominant CMVpp65-Specific Central Memory and Effector Memory T-Cells
Aisha Nasreen Hasan, MD

Prophylactic Donor Lymphocyte Infusion Prolongs Overall Survival after Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukaemia – Results from a Retrospective Matched Pair Analysis by the Acute Leukaemia Working Party
Christoph Schmid, MD

Safety and Preliminary Efficacy of “Ready to Administer” Cytomegalovirus-Specific T-Cells for the Treatment of Patients with Refractory CMV Infection
Ifigeneia Tzannou, MD

The Cost Effectiveness of Manufacturing Antigen-Specific T-Cells in an Academic GMP Facility
Patrick J. Hanley

Clonal Deletion Plays a Major Role to Achieve Tolerance after Reduced Intensity Unrelated Donor Cord Blood Transplantation
Paul Szabolcs, MD
Optimizing Anti-Thymocyte Globulin Exposure to Improve Survival Chances after Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome

Jaap-Jan Boelens, MD, PhD

A Prospective Observational Study to Evaluate a Cytomegalovirus-Specific Enzyme-Linked Immunospot Assay in Allogeneic Hematopoietic Cell Transplant Recipients: The REACT Study

Roy F. Chemaly, MD, MPH

The Impact of Pre- and Week 4 Post-Transplant CMV-Specific Elispot Assay on CMV Reactivation and Survival in CMV-Seropositive Allogeneic Hematopoietic Cell Transplant Recipients

Roy F. Chemaly, MD, MPH

Application of the CIBMTR Survival Outcomes Calculator to CD34-Selected Allogeneic HCT for Acute Leukemia and Myelodysplastic Syndrome

Christina Cho, MD

Combining the Disease Risk Index and Hematopoietic Cell Transplantation Comorbidity Index Provides a Comprehensive Prognostic Model for CD34-Selected Allogeneic HCT

Christina Cho, MD

Disease Characteristics and Overall Survival in Pediatric Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia after Stem Cell Transplantation

Alessandro Crotta
4:45 pm – 6:15 pm
Oral Abstracts – Session F: Infectious Disease
Florida Hall C
Moderators: Michael J. Boeckh, MD and Jose F. Camargo, MD

Outcomes after Allogeneic Hematopoietic Cell Transplantation with Donors or Recipients Harboring Inherited Chromosomally Integrated HHV-6
Joshua A. Hill, MD

Impact of Respiratory Virus Infection before Hematopoietic Cell Transplantation on Post-Transplant Outcomes in Adults in the PCR Era: Do Rhinovirus and Coronavirus Infections Matter?
Yae-Jean Kim, MD, PhD

Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study
Genovefa A. Papanicolaou, MD

Treatment of Adenovirus Infection in Allogeneic Hematopoietic Cell Transplant Patients with Brincidofovir: Final 36 Week Results from the Advise Trial
Vinod K. Prasad, MD

Prospective Assessment of Diagnostic Infectious Disease Molecular PCR Testing with Early Fiberoptic Bronchoscopy in the Evaluation of New Pulmonary Infiltrates in Hematopoietic Stem Cell Transplantation and Acute Leukemia Patients
Melissa Sanacore, PharmD

Administration of Banked, 3rd Party Multivirus-Specific T-Cells to Treat Drug-Refractory EBV, CMV, AdV, HHV6, and BKV Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Ifigeneia Tzannou, MD
FRIDAY, February 24

FRIDAY CONVENTION SERVICES:

6:00 am – 6:00 pm
Speaker Ready Room
Tampa 3

7:00 am – 6:00 pm
Internet Access Center and Charging Lounge
City Hall Lobby

7:00 am – 6:00 pm
Registration Open
Exhibit Hall Lobby F

FRIDAY EXHIBITS:

7:00 am – 2:00 pm
Exhibits Open
Exhibit Hall F

9:00 am – 5:00 pm
BMT Tandem Poster Session II
Set-Up and Preview
Florida Hall B

FRIDAY COMMITTEE MEETINGS:
Open to All Attendees

7:00 am – 8:30 am
ASBMT Infectious Disease Special Interest Group Meeting
Sun 4–6

7:30 am – 8:30 am
Improving Clinical Outcomes with FACT Accreditation
Sanibel 1–3

10:30 am – Noon
Statistical Consulting with CIBMTR PhD Biostatisticians
Sarasota 1

12:15 pm – 2:15 pm
CIBMTR Working Committee Meeting:
Graft-Versus-Host Disease
Osceola 4–6
Supported by a grant from Gilead Sciences, Inc.
FRIDAY COMMITTEE MEETINGS:
Open to All Attendees

12:15 pm – 2:15 pm
CIBMTR Working Committee Meeting:
Health Services and International Studies
Osceola 1-3

12:15 pm – 2:15 pm
CIBMTR Working Committee Meeting:
Regimen-Related Toxicity
Naples 1-3

4:00 pm – 5:00 pm
Transplant Nursing Special Interest Group
Steering Committee Meeting
Osceola D

6:45 pm – 8:45 pm
LABMT – Latin America Blood and Marrow
Transplant Group Meeting
Tallahassee 1-3

FRIDAY COMMITTEE MEETINGS:
By Invitation

7:00 am – 8:30 am
Pediatric BMT Program Planning Meeting
for 2018
Sun 1

7:00 am – 8:30 am
ASBMT/CIBMTR/NMDP Leadership Meeting
St. George #106

7:00 am – 8:30 am
Naïve T-Cell Depletion for Prevention of
Chronic GVHD (NTCD) Investigators Meeting
Orange Blossom Ballroom

10:30 am – 1:30 pm
WBMT Board Meeting
Miami 1-3

10:30 am – 2:30 pm
ASBMT Board of Directors Meeting
Orange Blossom Ballroom
FRIDAY PERIPHERAL CONFERENCES:

8:15 am – 5:00 pm
BMT Pharmacists Conference
Osceola A
See page 95 for agenda

8:15 am – 5:30 pm
BMT Clinical Education Conference
(for NPs, PAs, Fellows and Junior Faculty)
Osceola C
See page 91 for agenda

8:30 am – 4:00 pm
Transplant Nursing Conference
Osceola D
See page 100 for agenda

8:30 am – 5:55 pm
Administrative Directors Conference
Sun A
See page 89 for agenda

BREAKFAST OPTIONS

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

BMT TANDEM BREAKFAST SYMPOSIUM:

7:00 am – 8:00 am
Maximizing Patient Outcomes in Myelofibrosis: Stem Cell Transplantation in the JAK Inhibitor Era
Florida Hall D

Welcome and Introductions
Nicolaus Kröger, MD

Where Does Allogeneic HCT Fit in the JAK Inhibitor Treatment Era?
Vikas Gupta, MD

Combinations for Potential Cures in MF:
Integrating Transplant with JAK Inhibitors
Nicolaus Kröger, MD

Thoughts on Combined Modality Care in MF and Ask-the-Experts Q&A
Nicolaus Kröger, MD and Vikas Gupta, MD

This activity is supported by an educational grant from Incyte Corporation.
BREAKFAST SYMPOSIUM:

7:00 am – 8:00 am
Utilizing CAR T-Cells for Hematologic Malignancies in the Transplant Setting
Florida Hall E

Introduction
Stephan A. Grupp, MD, PhD

Update of Current Clinical Trials Using CAR T-Cells
Stephan A. Grupp, MD, PhD

CAR T-Cell Therapy for Hematological Malignancies Other than CD19
Helen E. Heslop, MD

Discussion/Q&A

This activity is supported by an educational grant from Kite Pharma, Inc. and Novartis Pharmaceuticals Corporation.

SCIENTIFIC PLENARY SESSION

8:30 am – 10:00 am
Acute GVHD
Florida Hall E
Chair: James Ferrara, MD, DSc

Antigen Presentation in Acute GVHD
Motoko Koyama, MD, PhD

The Microbiome in Acute GVHD
Ernst Holler, MD, PhD

Biomarkers in Acute GVHD
James Ferrara, MD, DSc

10:00 am – 10:30 am – Break
Randomized Trial of Inpatient Palliative Care Intervention for Patients Hospitalized for Hematopoietic Stem Cell Transplantation
Areej R. El-Jawahri, MD

Prediction of Opioid Requirement for Mucositis by Genotype in Children Undergoing Hematopoietic Cell Transplantation
M. Christa Krupski, DO, MPH

Increased Vitamin D Binding Protein Levels are Associated with Improved Overall Survival following Bone Marrow Transplant in Children
Nathan Luebbering, MS

Adipokine Concentrations and Adiposity in Hematopoietic Cell Transplant Survivors
Tyler G. Ketterl, MD

A Risk-Adapted Protocol of Prophylactic Zoledronic Acid Prevents Bone Mineral Density Loss Post-Allograft: Results of the ALLG BM07 Phase II Prospective Trial
Eric Wong

Understanding Physicians’ Perspectives about Translating Research into Clinical Practice: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Results
Nandita Khera, MD
10:30 am – Noon
Oral Abstracts – Session H: Pediatric Disorders
Florida Hall C
Moderators: Carrie L. Kitko, MD and Margaret L. MacMillan, MD, MSc

Reduced Intensity Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease: Results of a Phase I Trial
Allistair Abraham, MD

Incorporating Immunocytokine and Ex Vivo Expanded NK Cells to Improve Allogeneic Bone Marrow Transplant for Neuroblastoma
Christian M. Capitini, MD

Challenges with Diagnosing Pulmonary Chronic GVHD in Children as per the 2014 National Institutes of Health Consensus Criteria: Applied Biomarkers of Late Effects/Pediatric Blood and Marrow Transplant Consortium 1202 Study
Geoff D.E. Cuvelier, MD

Neurologic-Event-Free Survival: A New Endpoint for Severe Combined Immunodeficiency Patients Diagnosed by Newborn Screening and Treated with Hematopoietic Cell Transplantation
Christopher C. Dvorak, MD

Haploidentical Hematopoietic Stem Cell Transplantation using Tcrαβ/CD19 Depleted Grafts in Children with High-Risk Leukemia
Marta Gonzalez, MD, PhD

T-Cell Costimulation Blockade with Abatacept along with Pre-Transplantation Sirolimus and Post-Transplantation Cyclophosphamide Promotes Early Recovery of Tregs and Reduces Early Alloreactivity after Haploidentical PBSCT for Severe Aplastic Anemia
Sarita Jaiswal, BSc, MD
10:30 am – Noon
Oral Abstracts – Session I: Autologous Transplants
Florida Hall D
Moderators: Sergio A. Giralt, MD and Emma C. Morris, MD, PhD

A Phase 1/2 Trial of Carfilzomib + High-Dose Melphalan Conditioning for Auto-HCT followed by Carfilzomib Maintenance for Patients with Relapsed Multiple Myeloma
Luciano J. Costa, MD, PhD

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma in First Complete Remission
Zachariah M. DeFilipp, MD

Trends in Survival Outcomes Among Patients Relapsing Early after Autologous Stem Cell Transplantation for Multiple Myeloma (CIBMTR Study # MM14-03)
Angela Dispenzieri, MD

Autologous Stem Cell Transplantation with Benda-CV in Non-Hodgkin and Hodgkin Lymphoma Patients
Gregorio Jaimovich

Infusion of Autograft Natural Killer Cells/CD14+HLA-DRDIM Myeloid-Derived Suppressor Cells Ratio Predicts Survival in Non-Hodgkin Lymphoma Undergoing Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation
Ankit J. Kansagra, MD

Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study
Pritesh Rajni Patel, MB, ChB

LUNCH OPTIONS

Noon – 1:15 pm – BMT Tandem Buffet
Exhibit Hall F
Refer to page 4 for a variety of lunch options.
MEET-THE-PROFESSOR SESSIONS:
Meet-the-Professor luncheon tickets are $35, available for purchase at the BMT Tandem Meetings Registration Desk and subject to availability.

12:15 pm – 1:30 pm
All Things HLH
Sun 1
  *Rebecca A. Marsh, MD*

12:15 pm – 1:30 pm
Special Considerations in HCT for Patients with Sickle Cell Disease
Sun 2
  *Nicolas Novitzky, MD, PhD*

BMT TANDEM LUNCHEON SYMPOSIUM:
12:30 pm – 1:30 pm
Maximizing Outcomes with Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Florida Hall E

  Welcome and Introduction: HCT and Novel Therapy in AML – What are the Implications?
    *Jeffrey E. Lancet, MD*
  
  HCT in AML and the Impact of Novel Therapies
    *Jeffrey E. Lancet, MD*
  
  Optimizing Post-HCT Outcomes in AML: What Can Clinicians Do?
    *Robert J. Soiffer, MD*
  
  Thoughts on the Changing Role of HCT in AML and Audience Q&A
    *Jeffrey E. Lancet, MD and Robert J. Soiffer, MD*

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

CIBMTR GENERAL ASSEMBLY

2:45 pm – 3:00 pm
Florida Hall E
ASBMT BUSINESS MEETING

3:00 pm – 3:15 pm
Florida Hall E

BMT TANDEM BEST ABSTRACTS SESSION

3:15 pm – 5:00 pm
Florida Hall E
Co-Chairs: Marcel R.M. van den Brink, MD, PhD and David I. Marks, MBBS, PhD

Novel Genetic Variants Associated with Death Due to Acute Lymphoblastic Leukemia within One Year after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT Study)

Theresa E. Hahn, PhD

Ruxolitinib Prevents Cytokine Release Syndrome after CAR T-Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S. Kenderian, MD

A Novel Therapeutic Strategy to Control Conventional T-Cells while Supporting Treg Reconstitution Post-Transplant: Long-Term GVHD-Free Survival By Combining OX40L Blockade with Rapamycin

Victor Tkachev, PhD

Monitoring of MRD before and after Allogeneic Hematopoietic Cell Transplantation of Childhood ALL By FC and RQ-PCR: A Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, the PBMTC, the I-BFM and the Westhafen-Intercontinental-Group

Michael A. Pulsipher, MD

Myeloablative Autologous Transplantation of CD34+ Selected Hematopoietic Stem Cells Versus Monthly Intravenous Cyclophosphamide for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial

Keith Sullivan, MD

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of Inactivated VZV Vaccine in Recipients of Autologous Hematopoietic Cell Transplants

Drew J. Winston, MD
CIBMTR AND ASBMT AWARDS

5:00 pm – 5:30 pm
Florida Hall E

CIBMTR AWARDS:

CIBMTR Distinguished Service Award
Presented to David Gómez-Almaguer, MD and Guillermo J. Ruiz-Argüelles, MD

The CIBMTR collaborates with the global scientific community to advance HCT and cellular therapy research worldwide. The purpose of the Distinguished Service Award is to recognize individuals who have made outstanding contributions to the CIBMTR’s research mission in one or more of the following areas: promoting HCT research and clinical care in developing countries; advancing the field despite unique challenges; expanding the availability of transplantation; disseminating research results to clinicians and patients to improve outcomes and quality of life; and collaborating with organizations to increase data exchange and research collaboration worldwide.

Dr. David Gómez-Almaguer is head of Hematology at the University Hospital in Monterrey Mexico, and Director of the Stem Cell Transplantation Program, the only FACT accredited program in Mexico. He is a member of the American Society of Hematology, American Society of Clinical Oncology, International Society of Hematology, ASBMT and CIBMTR, and Past President (2009-2011) of Mexican Society of Hematology (AMEH). He was Chair of the CIBMTR’s International Studies Working Committee representing Mexico, Central and South America from 2009-2011. He is a member of the National Academy of Medicine in Mexico, Mexican Academy of Science and National System of Investigators. He is also Secretary General of the Inter-American Division of the International Society of Hematology and President of the Mexican Society of Stem Cell Transplantation. Dr. Gómez-Almaguer has published over 200 articles in Mexican and international journals, and several chapters in books. He is also Editor of the journal Medicina Universitaria, and three books, and has received several awards in recognition for his research.

…continued on next page
Dr. Guillermo J. Ruiz-Argüelles is Director of Research of Clinica Ruiz, founded by his grandfather in 1920, and Director General of the Centro de Hematología y Medicina Interna de Puebla. He reached the highest level (III) in the Sistema Nacional de Investigadores, and was appointed a member of the Academia Nacional de Medicina, the Academia Mexicana de Ciencias, a fellow of the American College of Physicians (ACP) and of the Royal College of Physicians and Surgeons of Glasgow. He was President of the Mexican Society of Internal Medicine (1989), President of the Mexican Society of Hematology (1994–1995), Chair of Council for the International Society of Hematology (ISH) (2005-2009) and President of ISH (2010–2012). In 2011 he was named Mayo Clinic Distinguished Alumnus, in 2013 he was elected Master of the ACP and in 2016 Governor of the Mexican Chapter of the ACP. Dr. Ruiz-Argüelles has published over 400 papers in peer-reviewed journals, 78 letters to the editor and 356 abstracts. He is the editor of seven books, the editor of the Revista de Hematología, and a member of the editorial board of several journals. The main areas of his research and patient care are bone marrow transplantation, treatment of hematological malignancies, coagulation and thrombosis.

Dr. Gómez-Almaguer and Dr. Ruiz-Argüelles receive this award for their service and commitment to the CIBMTR and its missions. They have focused their efforts on making changes to BMT procedures to render them affordable for persons living in developing countries; employing these changes, they have grafted more than 1,000 persons with both malignant and non-malignant diseases.
ASBMT AWARDS:

ASBMT Lifetime Achievement Award
Presented to Hans Messner, MD, PhD

Dr. Hans Messner is Professor of Medicine at the University of Toronto and Princess Margaret Cancer Centre, Toronto, Ontario, Canada. His legacy to the global transplant community is vast, having contributed substantially to the scientific, administrative and educational components of BMT for over four decades. In 1970, he established the first and largest BMT Program in Canada. In doing so, he has trained and mentored scores of Canadian and international BMT trainees, many of whom have since set up their own clinical or research programs in BMT. He is the founding President of the Canadian Blood and Marrow Transplant Group (CBMTG), a multidisciplinary organization that represents Canadian health professionals and scientists in the field of BMT. Among his many scientific achievements, was the first description of a clonal assay for human pluripotent hematopoietic progenitors in culture (CFU-GEMM), the first description of pluripotent hematopoietic progenitors in human cord blood, the description of the role of clonogenic progenitors in stem cell allografts, and, together with Drs. L. Smith and E.A. McCulloch, the first description of biphenotypic leukemia.
BBMT Editorial Awards

Ernest McCulloch and James Till Award
Ahmad Rayes, MD

George Santos Award
Carmen Di Grazia, MD

ASBMT New Investigator Awards
Each year, the American Society for Blood and Marrow Transplantation is proud to sponsor the research initiatives of new investigators in the field of HCT. We gratefully acknowledge the following sponsors for their generous support of this important initiative:

The ASBMT/Amgen New Investigator Award
Supported by ASBMT and Amgen, Inc.
Tessa Minchen Andermann, MD, MPH

The ASBMT/Celgene New Investigator Award
Supported by ASBMT and Celgene Corporation
Armin Rashidi, MD, PhD

The ASBMT/Sanofi Genzyme New Investigator Award
Supported by ASBMT and Sanofi Genzyme
Ya-Yuan Fu, PhD

The ASBMT/Takeda Oncology New Investigator Award
Supported by ASBMT and Millennium, the Takeda Oncology Co.
Shuichiro Takashima, MD, PhD
MORTIMER M. BORTIN LECTURE

5:30 pm – 6:00 pm
Florida Hall E

Use and Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Targeted Therapies

Richard E. Champlin, MD

Dr. Richard Champlin is currently Professor and Chairman, Department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center in Houston, TX. He has more than 30 years of experience in clinical and translational research involving hematopoietic stem cell transplantation (HCT). Dr. Champlin is also Past President of the American Society of Blood and Marrow Transplantation, and Past Chair of the Advisory Committee for the Center for International Center for Blood and Marrow Transplantation Research. He is a previous Board Member of the National Marrow Donor Program and of the HRSA Advisory Committee for Blood Stem Cell Transplantation. His Department at the MD Anderson Cancer Center has a major research focus to develop novel approaches to improve the efficacy of HCT for treatment of malignancy and hematologic disorders, as well as to prevent the major complications, graft-versus-host disease and infections. He has a major interest in expanding access to HCT for older patients, and patients lacking an HLA-matched donor, using haploidentical and cord blood transplants. Under his direction, MD Anderson Cancer Center has been a leading institution in enrollment of patients on clinical research studies of the BMT CTN and committed to continued enrollment and participation in this important research. His department has a major research focus on cellular therapies and immune modulation to eradicate malignancy and improve disease-free survival. Dr. Champlin is actively investigating the therapeutic use of ex vivo expanded NK cells and chimeric antigen receptor T-Cells to enhance the outcome of HCT and as stand-alone cellular immune therapy.

The Mortimer M. Bortin Lecture commemorates the Founding Scientific Director of the International Bone Marrow Transplant Registry (IBMTR, forerunner of the CIBMTR), whose foresight and dedication were critical to the development of the CIBMTR as a global resource for HCT research. Lecturers are chosen on the basis of their contributions to our understanding of Graft-Versus-Tumor effects and/or the advancement of clinical HCT research.
Modulating Immune Reconstitution after Stem Cell Transplantation

Jerome Ritz, MD

Dr. Jerome Ritz is Professor of Medicine, Harvard Medical School. His research laboratory focuses on reconstitution and maintenance of donor immunity after allogeneic hematopoietic stem cell transplantation (HCT). In this setting, there is compelling evidence that donor immunity plays a critical role in elimination of residual tumor cells (termed graft-versus-leukemia or GVL) as well as graft-versus-host disease (GVHD). Individual projects focus on the role of T-cells, regulatory T-cells, NK cells and B-cells in GVL and GVHD. Mechanistic studies focus on the identification of specific antigenic targets of T, B and NK cell responses and how these immune responses are maintained and regulated in vivo. All of the studies are carried out with samples obtained from patients undergoing stem cell transplantation and lay the foundation for the development of novel methods to specifically modulate immune reconstitution and tumor immunity following HCT. Dr. Ritz is also the Executive Director of the Cell Manipulation Core Facility (CMCF) of the Dana-Farber/Harvard Cancer Center. The CMCF is a GMP cell manufacturing facility that provides a variety of cellular products for patients enrolled on clinical research protocols, including hematopoietic stem cells, cancer vaccines, immune cells for adoptive therapy, genetically modified hematopoietic stem cells and immune cells and cells for regenerative medicine. As well, Dr. Ritz is Director of the Pasquarello Tissue Bank for Hematologic Malignancies at DFCI and Associate Director for Core Facilities and member of the Executive Committee of the Dana-Farber/Harvard Cancer Center.

In honor of Dr. Thomas, the E. Donnall Thomas Lecture recognizes an eminent physician or scientist, either a clinician or investigator, who has contributed meritoriously to the advancement of knowledge in blood and marrow transplantation.
Saturday, February 25

SATURDAY CONVENTION SERVICES:

6:00 am – 6:00 pm
Speaker Ready Room
Tampa 3

7:00 am – 6:00 pm
Internet Access Center and Charging Lounge
City Hall Lobby

7:00 am – 6:00 pm
Registration Open
Exhibit Hall Lobby F

SATURDAY EXHIBITS:

7:00 am – 2:00 pm
Exhibits Open
Exhibit Hall F

2:00 pm – 6:00 pm
Exhibit Move-Out
Exhibit Hall F

9:00 am – 5:00 pm
BMT Tandem Poster Session II Viewing
Florida Hall B

6:45 pm – 7:45 pm
BMT Tandem Poster Session II – Meet the Authors
Florida Hall B
Session II Posters must be removed by 9:00 pm on Saturday.
SATURDAY COMMITTEE MEETINGS:
Open to All Attendees

12:15 pm – 2:15 pm
ASBMT Cord Blood Special Interest Group Meeting
Tallahassee 1-3

12:15 pm – 2:15 pm
CIBMTR Working Committee Meeting: Infection and Immune Reconstitution
Osceola 1-3
Supported by a grant from Astellas Pharma US, Inc.

12:15 pm – 2:15 pm
CIBMTR Working Committee Meeting: Pediatric Cancer
Osceola 4-6

2:45 pm – 4:45 pm
CIBMTR Working Committee Meeting: Chronic Leukemia
Osceola 1-3

2:45 pm – 4:45 pm
CIBMTR Working Committee Meeting: Donor Health and Safety
Naples 1-3

5:00 pm – 5:30 pm
ASBMT NP/PA Special Interest Group Business Meeting
Osceola C
SATURDAY COMMITTEE MEETINGS:
By Invitation

7:00 am – 8:30 am
CIBMTR Mismatched Unrelated Donor (15-MMUD) Transplant PI/Coordinators Meetings
Sanibel 1-3

7:00 am – 8:30 am
NMDP Education Consortium Meeting
St. George #112

7:30 am – 8:30 am
ASBMT Special Interest Group Chair Meeting with President
St. George #104

7:30 am – 8:30 am
CIBMTR Kepivance Study Protocol Team Meeting
St. George #106

10:00 am – 11:30 am
BMT Tandem Scientific Organizing Committee Meeting for 2018
Orange Blossom Ballroom

1:30 pm – 2:30 pm
ASBMT Clinical Research Training Course Reunion
Emerald Bay Plaza: Wedding Pavilion

4:00 pm – 6:00 pm
Transplant Nursing Conference Planning Team Meeting for 2018
Sun 1

5:00 pm – 6:00 pm
BMT Pharmacists Conference Planning Meeting for 2018
Osceola A

5:30 pm – 6:30 pm
Clinical Education Conference Planning Committee Meeting for 2018
Osceola C

6:30 pm – 7:45 pm
Amy Strelzer Manasevit Research Program Reception
St. George #114
SATURDAY PERIPHERAL CONFERENCES:

8:15 am – 4:45 pm  
BMT Pharmacists Conference  
Osceola A  
See page 97 for agenda

8:15 am – 6:00 pm  
BMT Clinical Education Conference  
(for NPs, PAs, Fellows and Junior Faculty)  
Osceola C  
See page 93 for agenda

8:30 am – 3:45 pm  
Transplant Nursing Conference  
Osceola D  
See page 101 for agenda

12:15 pm – 4:45 pm  
Building a Patient-Centered Outcomes Research (PCOR) Collaborative Community  
Sun A  
See page 85 for agenda

BREATFAST OPTIONS

6:30 am – 8:15 am – Continental Breakfast Buffet  
Exhibit Hall F

BMT TANDEM BREAKFAST SYMPOSIUM:

7:00 am – 8:00 am  
Optimal Use of Stem Cell Mobilization in Patients with Hematologic Malignancies  
Florida Hall D

Introduction  
Parameswaran N. Hari, MD, MS

Barriers to Transplantation in Myeloma  
Parameswaran N. Hari, MD, MS

Mobilizing Strategies and Goals  
Luciano J. Costa, MD, PhD

Panel Discussion

This activity is supported by an independent educational grant from Sanofi Genzyme.
BMT TANDEM BREAKFAST SYMPOSIUM:

7:00 am – 8:00 am
Updates on Hematologic Malignancies:
New, Targeted Conditioning Regimens
Florida Hall E

Welcome and Introduction
Sergio A. Giralt, MD

Dose Intensity in MDS and AML:
Does it Matter?
Bart L. Scott, MD

Novel Conditioning Regimens for Adults with ALL
David I. Marks, MBBS, PhD

Clinical Outcomes of New and Emerging Targeted Conditioning Regimens
Sergio A. Giralt, MD

Question and Answer Session

This activity is supported by an independent educational grant from Actinium Pharmaceuticals.
ASBMT PRESIDENT’S SYMPOSIUM:

8:30 am – 10:00 am
Carpe Diem: Palliative Care, Helping Patients Make the Most of Every Day

The ASBMT President’s Symposium is dedicated to excellence in patient care and provides information, education, professional development and advocacy strategies to promote the delivery of quality blood and marrow transplantation and cellular therapy. The symposium is designed for BMT leaders and covers important current issues. In past years, the focus has been on center factors influencing transplant outcomes, economic outcome measures, reimbursement, overcoming current barriers to transplant and systems capacity. The 2017 forum will focus on the growing importance of quality palliative care and its profound impact on HCT patients.

Florida Hall E
Chair: Effie Petersdorf, MD

Palliative Care: 21st Century Person-Centered Care for Those Facing a Serious Illness
Thomas W. LeBlanc, MD, MA

Palliative Care Integration in Oncology: The Evidence and Lessons Learned
Areej R. El-Jawahri, MD

It’s a Perfect Match: Together HCT and Palliative Care Help Patients Live and Live Well
Christina Ullrich, MD, MPH

10:00 am – 10:30 am – Break
CONCURRENT SCIENTIFIC SESSIONS

10:30 am – Noon
WBMT Joint International Session:
Do Stem Cell Transplants Need to Be So Expensive?
Florida Hall D
Co-Chairs: Yoshibisa Kodera, MD, PhD and Jeffrey Szer, MBBS

WBMT Introduction
Jeffrey Szer, MBBS

Introduction to the Topic of Cost
Daniel J. Weisdorf, MD

The Mexican Experience
David Gómez-Almaguer, MD

What is Really Necessary? The Indian Experience
Alok Srivastava, MD

10:30 am – Noon
Chronic GVHD
Florida Hall E
Chair: Bruce R. Blazar, MD

Preclinical Immune Regulatory Strategies to Treat Chronic GVHD
Bruce R. Blazar, MD

Targeting Tregs in Human Chronic GVHD
Jerome Ritz, MD

Chronic GVHD Biomarkers and Application
Sophie Paczesny, MD, PhD

10:30 am – Noon
Statistical Issues in Transplant Data
Florida Hall C
Chair: Brent R. Logan, PhD

An Introduction to Adaptive Treatment Strategies
Erica C. Moodie, PhD

Flexible Predictive Modeling using Trees and Random Forests
Brent R. Logan, PhD

P-Values in Clinical Research: Friend or Foe?
Ted Alan Gooley, PhD
LUNCH OPTIONS

Noon – 1:15 pm – BMT Tandem Buffet
Exhibit Hall F

MEET-THE-PROFESSOR SESSIONS:

Meet-the-Professor luncheon tickets are $35, available for purchase at the BMT Tandem Meetings Registration Desk and subject to availability.

12:15 pm – 1:30 pm
How Do I Work-Up and Treat Transplant-Associated Microangiopathy (TAM)?
Sun 1
  Joseph H. Antin, MD

12:15 pm – 1:30 pm
How to Propose a Successful Registry Study with CIBMTR
Sun 2
  Steven M. Devine, MD

BMT TANDEM LUNCHEON SYMPOSIUM:

12:30 pm – 1:30 pm
Emerging Approaches to Target the Immunologic Chaos of GVHD
Florida Hall E

Welcome, Introductions and Baseline Assessment
  Corey S. Cutler, MD, MPH

Current Management of Graft-Versus-Host Disease
  Corey S. Cutler, MD, MPH,
  John F. DiPersio, MD, PhD and
  David Miklos, MD, PhD

Novel and Emerging Therapies for Graft-Versus-Host Disease
  Corey S. Cutler, MD, MPH,
  John F. DiPersio, MD, PhD and
  David Miklos, MD, PhD

Audience Questions, Post-Activity Assessment

This activity is supported by an educational grant from Incyte Corporation and Pharmacyclics, LLC.
Using Haplogic™ and Recipient Ancestry: The Likelihood of Identifying an 8/8 HLA-Matched Unrelated Donor Can be Accurately Predicted at the Time of the Preliminary Search Markedly Improving Search Efficiency and Speed to Allograft: An 830 Patient Analysis

**Eric Davis, CHTC**

Donor-Lymphocyte Infusion following Haploidentical Hematopoietic Cell Transplantation with Peripheral Blood Stem Cell Grafts and PTCy

**Scott R. Goldsmith, MD**

Maintenance Therapy with Azacitadine and Valproic Acid after Allogeneic Stem Cell Transplant in Patients with High-Risk Acute Myelogenous Leukemia

**Patrick A. Hagen**

Prognostic Impact of Variant Allelic Frequency of Molecular Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes on Allogeneic Hematopoietic Cell Transplant Outcomes

**Betty Ky Hamilton, MD**

Impact of CYP3A5/CYP2C19 Pharmacogenetics on Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Using Tacrolimus/Sirolimus as Graft-Versus-Host Disease Prophylaxis

**Samer K. Khaled, MD**

High Exposure to Fludarabine in Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Predicts for Impaired CD4 Reconstitution and Lower Survival Chances

**Jurgen Langenhorst, PharmD**

Allogeneic Transplant for Mixed Phenotype Acute Leukemia: Characteristics and Outcome in the ALWP-EBMT Database

**Reinhold Munker, MD**
Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402
Shernan Holtan, MD

4:45 pm – 6:45 pm
Oral Abstracts – Session K:
Alternative Donors and GVH/GVL
Florida Hall E
Moderators: Veronika Bachanova, MD, PhD and Motoko Koyama, MD, PhD

A Novel Pre-Transplant Immunosuppressive Preparative Regimen for Myeloablative Haploidentical and Unrelated Donor Hematopoietic Transplant in Hemoglobinopathies: A Safe and Effective Approach
Sunil Bhat

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for 41 Children and Adolescents with Bone Marrow Failures
Carmin Bonfim, MD, PhD

Haploidentical Stem Cell Transplantation with CD3+/CD19+ Depleted Peripheral Stem Cells for Advanced Stage Sickle Cell Disease
Selim Corbacioglu, MD

Fever Post-Infusion of T-Cell Replete HLA-Mismatched Haploidentical Hematopoietic Stem Cells
Melhem Solh, MD

CD56 Enriched Donor Cell Infusion following Post-Transplantation Cyclophosphamide and Cyclosporine Alone for Haploidentical PBSCT in Myeloid Malignancies is Associated with Prompt Reconstitution of Mature NK Cells and Tregs with Reduced Incidence of aGVHD
Sarita Jaiswal, BSc, MD

Analysis of the Impact of Donor Characteristics on Outcomes after 2-Step Haploidentical Hematopoietic Stem Cell Transplantation
Praveen Ramakrishnan Geethakumari, MD
Multi-State Modeling Identifies Determinants of Successful Immune Suppression Discontinuation: Secondary Analysis of BMT CTN 0201 and 0402 Trials  
Joseph A. Pidala, MD, PhD

Deletion of AMP-Activated Protein Kinase in Donor T-Cells Protects Against Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Responses  
Craig Alan Byersdorfer, MD, PhD

4:45 pm – 6:45 pm  
Oral Abstracts – Session L: Allogeneic Transplants and Histocompatibility  
Florida Hall C  
Moderators: Leo Luznik, MD and Lazaros J. Lekakis, MD

Lindsey E. Roeker, MD

Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant in the Modern Era  
Mitchell Sabloff, MSc, MDCM

Impact of ABO-Mismatching following HLA-Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for AML – a Report from the ALWP of the EBMT  
Bipin N. Savani, MD

Comparable Survival with Organ Toxicity Predicting for Overall Survival and Non-Relapse Mortality in Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation  
Gunjan L. Shah, MD MS

Allogeneic Hematopoietic Cell Transplantation in the Eighth Decade of Life: How Much Does Age Matter?  
Mohamed L. Sorror, MD, MSc
Functional Genetic Variants on 14q32 Associate with Death Due to Acute Myeloid Leukemia and Myelodysplastic Syndrome within One Year after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT Study)

Lara Sucheston-Campbell, PhD

Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation

Shannon R. McCurdy, MD

Identifying Permissible HLA-Mismatches in Unrelated-Donor Hematopoietic Stem Cell Transplantation Using Predicted Indirectly Recognizable HLA Epitopes

Eric Spierings, PhD

BMT TANDEM POSTER SESSION II

6:45 pm – 7:45 pm
BMT Tandem Poster Session II – Meet the Authors
Florida Hall B

Session II Posters must be removed by 9:00 pm on Saturday.

BMT TANDEM MEETINGS RECEPTION:

8:00 pm – 1:00 am
Coquina Lawn and Fire Pits/Wreckers Nightclub, Gaylord Palms

Join ASBMT President, Christopher Bredeson, MD, MSc and CIBMTR Chair, Paul J. Martin, MD for an enjoyable evening of conversation, complimentary beverages and cuisine and dancing on Saturday, February 25. The evening will begin on the Coquina Lawn at the Gaylord Palms, then move into Wreckers Nightclub, just off the lawn, for dancing.

Tickets are available online and at the Registration Desk until Thursday, February 23 at 5:00 pm, subject to availability.
Sunday, February 26

SUNDAY CONVENTION SERVICES:

6:00 am – 12:30 pm
Speaker Ready Room
Tampa 3

7:00 am – 1:30 pm
Internet Access Center and Charging Lounge
City Hall Lobby

7:00 am – 1:30 pm
Registration Open
Exhibit Hall Lobby F

BREAKFAST OPTIONS

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall Lobby

SCIENTIFIC PLENARY SESSION

8:30 am – 10:00 am
CAR T-Cells and TCR Gene Therapy
Florida Hall E
Chair: Emma C. Morris, MD, PhD

Treatment of Lymphoma with Anti-CD19 CAR T-Cells
James N. Kochenderfer, MD

Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: How Close are We?
Saar I. Gill, MD, PhD

TCR Gene Therapy for AML and MDS
Emma C. Morris, MD, PhD

10:00 am – 10:30 am – Break
Results of a Phase II Clinical Trial of Tocilizumab, Tacrolimus and Methotrexate for the Prevention of Acute Graft-Versus-Host Disease and Matched Case Control Comparison to Tac/MTX after Allogeneic Stem Cell Transplantation

William Drobyski, MD

Deficiency of MyD88 Signaling in CD4 Tconvs Increases Tregs Suppression through Loss of ST2 Signaling, Reducing Acute Graft-Versus-Host Disease in Multiple Models

Brad Griesenauer, BS

Cytomegalovirus Antigenic Mimicry of Human Alloreactive Peptides: Exploring Cross-Reactivity as a Potential Trigger for Graft-Versus-Host Disease

Charles E. Hall, MS

Whole Exome Sequencing to Determine the Likelihood of Graft-Versus-Host Disease in Stem Cell Transplant Donor-Recipient Pairs

Amir A. Toor, MD

Biomarkers Predict Graft-Versus-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment

Hannah Major-Monfried

Extended Course of Maraviroc, a CCR5 Antagonist, is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study

Ran Reshef, MD
Venous Thromboembolism in Pediatric Recipients of Hematopoietic Stem Cell Transplant: A Multicenter Cohort Study
Hemalatha G. Rangarajan, MD

Individualized Dosing and Therapeutic Drug Monitoring of ATG is Feasible, Safe, Effective, and Associated with Excellent Immune Reconstitution
Caroline A. Lindemans, MD, PhD

Interleukin-22 Levels are Increased in Gastrointestinal Graft-Versus-Host Disease in Children
Dana T. Lounder, MD

Vitamin A and Gastrointestinal Graft-Versus-Host Disease in Children: Mechanistic Studies
Dana T. Lounder, MD

Second Hematopoietic SCT for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen
Vikram Mathews, MD

Noon – 12:30 pm – BMT Tandem Buffet
Exhibit Hall Lobby

12:30 pm – 1:30 pm
Late Breaking Abstracts
Florida Hall E
Moderators: Marcel R.M. van den Brink, MD, PhD and David I. Marks, MBBS, PhD

Pivotal Phase 2 Trial of Kte-C19 (anti-CD19 CAR T-Cells) in Patients with Refractory Aggressive NHL (ZUMA-1)
Frederick L. Locke, MD

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Letemovir for Prevention of Cytomegalovirus Infection in Adult CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
Francisco M. Marty, MD

Phase 2 Study of Ibrutinib in Patients with Chronic Graft-Versus-Host Disease Who Have Failed Frontline Systemic Therapy
David Miklos, MD, PhD

2017 BMT TAMDEM MEETINGS CONCLUDE
CIBMTR Clinical Research Professionals/Data Management Conference

The Clinical Research Professionals/Data Management Conference provides training and educational opportunities to data management staff responsible for completing and submitting recipient data to the CIBMTR.

The Medical College of Wisconsin designates this activity for up to 13.25 hours of participation for continuing education for allied health professionals attending the Clinical Research Professionals/Data Management (CRP/DM) Conference.

Tuesday, February 21

Osceola D

7:00 am – 8:15 am – CRP/DM Breakfast Buffet
Osceola D

7:30 am – 8:15 am
Breakfast with Dr. Mary M. Horowitz
Mary M. Horowitz, MD, MS

8:15 am – 8:30 am
Welcome/Staff Introductions
Sharon K. Meiers and Kay Gardner

8:30 am – 8:45 am
Mentors Update
Denise Bellman, CRC and Elizabeth Roberts

8:45 am – 9:30 am
CIBMTR Data Life Cycle
J. Douglas Rizzo, MD, MS

9:30 am – 10:00 am
VOD
Jennifer R. Willert, MD

10:00 am – 10:30 am – Break

10:30 am – Noon
Cellular Therapies – Science, Process, Forms
Bronwen E. Shaw, MD, PhD

Noon – 1:00 pm – CRP/DM Lunch Buffet
Osceola D
1:00 pm – 1:45 pm
Chronic GVHD
   *Stephanie J. Lee, MD, MPH*

1:45 pm – 2:15 pm
CMS Update
   *Rebecca J. Drexler*

2:15 pm – 2:45 pm – Break

2:45 pm – 3:30 pm
Molecular Markers
   *Marcie L. Riches, MD, MS*

3:30 pm – 4:15 pm
Cytogenetics
   *Daniel J. Weisdorf, MD*

4:15 pm – 4:45 pm
Hot Topics
   *Kay Gardner*

5:00 pm – 6:30 pm
CRP/DM Mentors’ Reception
St. Augustine: Castillo de San Marcos Fort – Upper Level
The Mentors’ Reception is a great opportunity to network and meet other Data Managers with whom you can connect throughout the year.

**Wednesday, February 22**

Osceola D

7:30 am – 8:30 am – CRP/DM Breakfast Buffet
Osceola D

8:30 am – 8:45 am
Welcome
   *Sharon K. Meiers and Kay Gardner*

8:45 am – 9:30 am
FACT/CIBMTR Audit Collaboration
   *Phyllis I. Warkentin, MD*

9:30 am – 10:00 am
Radiation Injury Treatment Network – Data Collection
   *Cullen Case*

10:00 am – 10:30 am – Break
10:30 am – Noon
Panel Discussion – Best Practices for Centers
Moderator: Bridget Wakaruk, SCM
Panelists: Emily Laskowski, Jason Parmentier, BSN, RN and Daniel Skolnick

Noon – 1:00 pm – CRP/DM Lunch Buffet
Osceola D

1:00 pm – 2:00 pm
CRP/DM Oral Abstracts

New Quality Improvement Plan for CIBMTR Data
Nicolette Maria Minas, MS, CCRP and Kathleen Rueble, RN

Training Tools to Ensure Accurate CIBMTR Data Reporting by New Research Coordinators
Angie Pavlescak

Development of Forms for a Tutorial of Transplant Essential Data as Facilitator to Understand and Learn about Data Entry to CIBMTR in Brazilian Centers
Cinthya Correa Silva

2:00 pm – 2:15 pm – Break

2:15 pm – 3:00 pm
Tools for Centers: Data for RFI
Erik Bergman, MBA, MS, Paul Gengler and Read Fritsch

3:00 pm – 3:30 pm
Forms Revision Updates/Changes
Emilie Love

3:30 pm – 4:00 pm
Method of Latest Disease Assessment
Ashley Birch and Mandi Proue

4:00 pm – 4:45 pm
Infection
Marcie L. Riches, MD, MS

Thursday, February 23

St. George #108

1:00 pm – 3:30 pm
International Data Managers Open Forum
Janet Brunner-Grady, PA-C, Allyson Draxler, MPH and Bridget Wakaruk, SC
CRP/DM In-Depth Training

The In-Depth Training for Clinical Research Professionals/Data Management will provide comprehensive training for a limited number of Clinical Research Professionals/Data Managers on subjects including Multiple Myeloma and Forms Journey – The What, When and Where. Registration for the training is available on-site at the BMT Tandem Meetings Registration Desk. Attendance is limited to 15 participants per session, and tickets are subject to availability. Note that only one person from each center may attend each session.

The Medical College of Wisconsin designates this activity for up to 4.0 hours of participation for continuing education for allied health professionals attending the In-Depth Training for Clinical Research Professionals/Data Management.

Thursday, February 23

Sanibel 1-3

9:00 am – 11:30 am
SESSION ONE: Basics of Multiple Myeloma

Basics of Multiple Myeloma with Amyloid
Anita D'Souza, MD, MS

10:00 am – 10:30 am – Break

Multiple Myeloma Reporting
Janet Brunner-Grady, PA-C

1:00 pm – 3:30 pm
SESSION TWO: Forms Journey
Andrea Benoit, Leigh Ann Laczkowski, Sue Logan, MS, CCRP, Elliott Michem, Alisba Mussetter and Tina Tbole

2:00 pm – 2:30 pm – Break
The BMT CTN Investigators Meeting is for investigators and clinical and research staff involved in BMT CTN studies. Physicians at centers interested in becoming involved in the BMT CTN are also welcome to attend.

The Medical College of Wisconsin designates this live activity for up to 1.0 contact hours of continuing education for allied health professionals attending the BMT CTN Investigators Meeting.

Wednesday, February 22

Sun B

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

7:00 am – 7:10 am
Welcome Address
Steven M. Devine, MD

7:10 am – 7:30 am
BMT CTN 0702 STaMINA Primary Results
Marcelo C. Pasquini, MD, MS

7:30 am – 7:45 am
BMT CTN 1506 FLT3+ AML Maintenance Therapy
Yi-Bin Chen, MD

7:45 am – 8:00 am
BMT CTN 0201 BM Versus PB: Five-Year Follow-Up Results
Stephanie J. Lee, MD, MPH

8:00 am – 8:15 am
Risk Stratified Trials in GVHD
Amin M. Alousi, MD
The BMT CTN Coordinators Meeting is for BMT CTN clinic and data coordinators, research nurses or other site staff involved with BMT CTN studies.

The Medical College of Wisconsin designates this activity for up to 5.25 hours of participation for continuing education for allied health professionals attending the BMT CTN Coordinators Meeting.

### Wednesday, February 22

#### Sun A

**6:30 am – 8:15 am** – Continental Breakfast Buffet  
Exhibit Hall F

**8:30 am – 8:35 am**  
Introductions  
*Ellen Parker, MBA*

**8:35 am – 8:55 am**  
Welcome Address  
*Adam Mendizabal, PhD*

**8:55 am – 9:35 am**  
Reporting Toxicities Panel Discussion  
*Katie McCray, Lisa Murray, MA, Marcie L. Riches, MD, MS and Audra Thompson, RN, BSN*

**9:35 am – 10:15 am**  
Roundtable Session I

**New: BMT CTN Basics and Resources**  
*Brianne Allison*

**Myeloma: Understanding SPEP/UPEP/Free Light Chains/Heavy Light Chains**  
*Kristin Knust, MS and Nina D. Shah, MD*

**Peds: BMT CTN 1502 Aplastic Anemia**  
*Amy E. DeZern, MD, MHS and Iris D. Gersten, MS*

**Sickle Cell: 1503 HLA-Matched HCT Clinical Protocol**  
*Mary Eapen, MD, MS and Courtney Nelson*

**Ad Hoc: Understanding Statistical Designs**  
*Adam Mendizabal, PhD and Maggie Wu, MS*
10:15 am – 10:30 am – Break

10:30 am – 11:00 am
Single IRB Policy and BMT CTN Implications
  Roberta J. King, MPH and Noah Tucker, CCRC

11:00 am – 11:30 am
Good Clinical Practices
  Denise King, MS

11:30 am – 12:10 pm
Roundtable Session II
  New: Basic Transplant Science
    Marcelo C. Pasquini, MD, MS and Terry Pritchard, MS
  Myeloma: Common Data Reporting Errors Found by Endpoint Review Committee
    Kristin Knust, MS and Philip L. McCarthy, MD
  Sickle Cell: BMT CTN 1507 Haplo SCD
    Brianne Allison and Adetola A. Kassim, MD, MS
  Ad Hoc: Core Center Performance Metrics
    Stacey Brown, Amy Foley, MA, CCRP and Maggie Wu, MS

12:10 pm – 12:45 pm – BMT CTN Lunch Buffet
  Sun A

12:45 pm – 1:15 pm
Preventing and Reporting Deviations
  Whitney Reid and Samantha Wilkins

1:15 pm – 1:55 pm
Cellular Therapy Clinical Trial Possibilities
  Catherine M. Bollard, MD

1:55 pm – 2:35 pm
Roundtable Session III
  New: Protocol Release to Activation Pathway
    Terry Pritchard, MS
  Myeloma: BMT CTN 1302 and 1401 Lab Samples: Best Practices
    Ashley Spahn, Stephanie Waldvogel and Samantha Wilkins
  Peds: Toxicities in Children
    Brianne Allison and Jennifer Baker, RN
  Sickle Cell: 1503 Data Management FAQ
    Courtney Nelson and Mark C. Walters, MD
Ad Hoc: Methods of Educating Patients about Randomized Clinical Trials
   Mary Eapen, MD, MS and Iris D. Gersten, MS

2:35 pm – 2:50 pm – Break

2:50 pm – 3:30 pm
Sickle Cell Disease: The Care Continuum
   Mark C. Walters, MD

3:30 pm – 4:15 pm
AE Reporting Changes
   Audra Thompson, RN, BSN

4:15 pm – 4:30 pm
Closing Remarks
   Steven M. Devine, MD
Building a Patient-Centered Outcomes Research (PCOR) Collaborative Community

This session will include interactive discussion presented by patients, caregivers and the co-chairs of six Working Groups: physical health and fatigue; emotional, cognitive and social health; financial burden; models of care delivery-survivorship and late effects; patient, caregiver and family education and support; and sexual health and relationships. Following the Working Group reports, additional research opportunities within PCORI, BMT CTN and CIBMTR will be presented, and we will discuss next steps in building a collaborative research community.

The Medical College of Wisconsin designates this activity for up to 4.0 hours of participation for continuing education for health professionals attending Building a Patient-Centered Outcomes Research (PCOR) Collaborative Community.

Saturday, February 25

Sun A

12:15 pm – 12:30 pm
Welcome/Background
Linda J. Burns, MD

12:30 pm – 3:45 pm
Working Groups’ Reports
Co-Chair and Patient/Caregiver Co-Presentations
Linda J. Burns, MD

Sexual Health and Relationships
Co-Chairs: Allison W. Loren, MD, MSce and D. Kathryn Tierney, RN, PhD

Physical Health and Fatigue
Co-Chairs: William A. Wood, MD, MPH and Christina Ullrich, MD, MPH

Emotional, Cognitive and Social Health
Co-Chairs: Beatrice Abetti, LCSW and Areej R. El-Jawahri, MD
Patient, Caregiver and Family Education and Support  
Co-Chairs: Kim Schmit-Pokorny, RN, MSN, OCN and Alva Roche-Green, MD

Models of Survivorship Care Delivery  
Co-Chairs: Mark B. Juckett, MD and Lakshmana Krishnamurti, MD

Financial Burden  
Co-Chairs: Susan Doughtie, MS and Staci Arnold, MD, MBA

3:45 pm – 4:30 pm  
Research Opportunities  
Ellen M. Denzen, MS

BMT CTN  
Mary M. Horowitz, MD, MS

RCI BMT  
Rebecca J. Drexler

4:30 pm – 4:45 pm  
Next Steps  
Linda J. Burns, MD
The Administrative Directors Conference provides updates and education for those involved in BMT program leadership and quality assessment and improvement. Anyone with an interest in quality, staffing, reimbursement and administrative best practices is welcome to attend.

**Nursing Education**
This activity has been submitted to the Oncology Nursing Society (ONS) for approval to award contact hours. ONS is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s COA.

**Medical Education**
The Medical College of Wisconsin designates this activity for up to 2.0 hours of participation for continuing education for allied health professionals attending the Administrative Directors Conference Health Economics Session.

**Thursday, February 23**

Sun A

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

7:00 am – 7:45 am
MEETING CANCELED: Administrative Directors Pre-Conference Demonstration: Administrator Toolkit

8:30 am – 9:00 am
Welcome and Special Interest Group Updates
  *Kent H. Walters, MBA and Tonya P. Cox, BSN, RN, OCN*

9:00 am – 10:00 am
CIBMTR Updates
  *J. Douglas Rizzo, MD, MS*

10:00 am – 10:15 am – Break

10:15 am – 11:00 am
CMS Billing: 2017 Medicare Coding, Billing and Reimbursement Updates: Major Changes to be Aware of!
  *Jugna Shah, MPH*
11:00 am – Noon

Best Abstracts Presentation

Best Abstracts Opening Presentation

Leslie S. Parran, RN, MS, AOCN, NE-BC, BMTCN

Implementation of a Program Assessment Across a Network of 7 HCT Programs to Assess Risks Associated with Clinical Outcome Based on the 2015 Center for International Blood and Marrow Transplant Research Transplant Center-Specific Survival Report

Rocky Billups, MS

Getting Ready for Engineered Cell Therapies – an Administrative Perspective

Amy Emmert, MScPH

Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation

D. Kathryn Tierney, RN, PhD

Noon – 1:15 pm – Lunch Buffet

Sun Lobby

1:15 pm – 2:15 pm

2017 Quality: Three Tools for Soaring in High Quality Action

Introduction

Therese Dodd, BA, MBA, RN, CPHQ, FNAHQ

When the Worst Happens: Handling Low Occurrences and High-Risk Unforeseen Events

Jennifer A. Christian, CHTC

Defining Competency to Empower Quality Professionals in a Clinical Setting

Amanda K. Hrnicek, MBA, LBBA

Setting Quality Standards and Tools for Managing BMT Data

Ryan Hillgruber

2:15 pm – 2:45 pm – Break

2:45 pm – 3:45 pm

Quality and Value in SCT Update

Ruth Brentari, MHA

3:45 pm – 4:30 pm

Staffing and the Transplant Center: BMT Data Management Staffing

Clint L. Divine, MBA, MSM
4:30 pm – 4:45 pm
Day One Wrap-up and Flash Evaluations
  Kent H. Walters, MBA and Tonya P. Cox, BSN, RN, OCN

4:45 pm – 6:00 pm
Administrative Directors Conference Reception
Sun Lobby
This activity is supported by an independent grant from Sanofi Genzyme.

Friday, February 24

Sun A

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

8:30 am – 9:00 am
Welcome and Day Two Review
  Kent H. Walters, MBA and Tonya P. Cox, BSN, RN, OCN

9:00 am – 10:00 am
Staffing Workgroup Presentation:
  Role of BMT Coordinator
  S. Elizabeth Sharf, BSN, RN, NE-BC, CHTC

10:00 am – 10:15 am – Break

10:15 am – 11:15 am
Business of HCT Session 1: MACRA and MIPS
  Stephanie A. Farnia, MPH

11:15 am – Noon
Implementing Cellular Therapies
  Partow Kebriaei, MD

Noon – 1:15 pm – Lunch Buffet
Sun Lobby

1:15 pm – 2:15 pm
Business of HCT Session 2:
  Economics in HCT and Pharma
  Alex Ganetsky, PharmD, BCOP

2:15 pm – 2:30 pm – Break

2:30 – 3:00 pm
Day Two Wrap-up, Overall Meeting Evaluations and
  Call for Volunteers
  Kent H. Walters, MBA and Tonya P. Cox, BSN, RN, OCN
HCT VALUE AND HEALTH ECONOMICS SESSION:

Sun A

3:00 pm – 3:15 pm
Introduction to Health Economics and Value Session
Richard T. Maziarz, MD and Linda J. Burns, MD

3:15 pm – 3:55 pm
Payer Advocacy Strategies
David Dickens, MD

3:55 pm – 4:15 pm
Reimbursement and Drug Pricing: A Physician Perspective
Vinay Prasad, MD, MPH

4:15 pm – 4:35 pm
Reimbursement and Drug Pricing: Industry Perspective
Nathan J. Dowden

4:35 pm – 4:50 pm
Panel Discussion

4:50 pm – 5:10 pm
Resource Allocation and Decision Making in Transplant Across National Borders
Lotbar B. Huebsch, MD

5:10 pm – 5:30 pm
Medical Tourism: Transplant as a Tourist Industry
Kurt C. Gunter, MD

5:30 pm – 5:45 pm
Panel Discussion

5:45 pm – 5:55 pm
Wrap-Up and Concluding Remarks
Linda J. Burns, MD
This program will update Nurse Practitioners, Physician Assistants, Fellows, and Junior Faculty on key highly applicable research and clinical care topics in the field of blood and marrow transplantation. Through lecture and case-based presentations, specialists in the field will discuss current treatment challenges faced by clinicians involved in the care of both adult and pediatric transplant patients. The Conference will also feature ample opportunity for interactive discussion and question/answer sessions.

The Medical College of Wisconsin designates this activity for up to 11.5 hours of participation for continuing education for allied health professionals attending the BMT Clinical Education Conference.

Friday, February 24

Osceola C

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

8:15 am – 8:30 am
Welcome
Jackie Dioguardi, PA-C

CONCURRENT SESSIONS

8:30 am – 9:15 am

BREAKOUT SESSION
Osceola C
BMT 101
Corey S. Cutler, MD, MPH

PEdiATRIC BREAKOUT SESSION
Osceola B
Transplant for Neuroblastoma
Gregory A. Yanik, MD
9:15 am – 10:00 am

BREAKOUT SESSION
Osceola C
Maintenance Therapy after HCT
  Bart L. Scott, MD

PEDIATRIC BREAKOUT SESSION
Osceola B
Haploidentical Transplant and Gene Therapy for Sickle Cell Disease
  Allistair Abraham, MD

10:00 am – 10:30 am – Break

10:30 am – 11:15 am

BREAKOUT SESSION
Osceola C
Infectious Diseases in BMT through Images
  Francisco M. Marty, MD

PEDIATRIC BREAKOUT SESSION
Osceola B
Preventing Graft-Versus-Host Disease in Pediatrics
  Sung Won Choi, MD

11:15 am – Noon

BREAKOUT SESSION
Osceola C
Neurologic Complications of HCT
  Lakshmi Nayak, MD

PEDIATRIC BREAKOUT SESSION
Osceola B
Outcomes of Allogeneic Transplant in Pediatric CML
  Sonali Chaudhury, MD

Noon – 1:15 pm – Lunch Buffet
Osceola Lobby
1:15 pm – 2:00 pm
BREAKOUT SESSION
Osceola C
Metabolic Syndrome and Cardiovascular Disease following Hematopoietic Cell Transplantation
Zachariah M. DeFilipp, MD

PEDIATRIC BREAKOUT SESSION
Osceola B
Nutrition Management during Pediatric Hematopoietic Cell Transplantation
Paula Charubas Macris, MS, RD, CSO

2:00 pm – 2:45 pm
Managing CAR T-Cell Complications
Osceola C
Angela Kirk, PA-C

2:45 pm – 3:30 pm
APPs Interested in Research: Come Get Involved
Randi Hoffmann, PhD, RN, CNP

3:30 pm – 5:30 pm
2017 Clinical Education Conference Welcome Reception
Osceola C

Saturday, February 25

Osceola C

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

8:15 am – 8:30 am
Welcome – Day Two
Jackie Dioguardi, PA-C

8:30 am – 9:15 am
APP Practice Issues: Roundtable Discussions
Surviving and Thriving When Things Don’t Go as Planned
Gabrielle Zecha, PA-C, MHA

9:15 am – 10:00 am
Steroid Refractory GVHD
Claudio Anasetti, MD

10:00 am – 10:30 am – Break
10:30 am – 11:15 am
Preventing and Managing Renal Complications  
Benjamin Laskin, MD, MS

11:15 am – Noon
BMT Radiology: Pulmonary Manifestations of Bone Marrow Transplant  
Aamer Chughtai, MD

Noon – 1:15 pm – Lunch Buffet  
Osceola Lobby

1:15 pm – 2:00 pm
Quality of Life  
Areej R. El-Jawahri, MD

2:00 pm – 2:45 pm
Sequelae of Nuclear Accidents  
Robert Peter Gale, MD, PhD

2:45 pm – 3:30 pm
Moral Distress  
Joyce L. Neumann, PhD, APRN, AOCN, BMTCN

3:30 pm – 4:00 pm – Break

4:00 pm – 5:00 pm
NP/PA Oral Abstract Presentations

Rare Case of HHV6 Encephalitis in Post Allogeneic Transplant Recipient  
Jamie Reynolds, PA-C

Improving the Percentage of Independent APP Visits: Breaking the “Shared Model” Rut  
Chris Rimkus, RN, MSN, AOCN

5:00 pm – 5:30 pm
NP/PA Special Interest Group Business Meeting  
Open to All Attendees

5:30 pm – 6:00 pm
NP/PA Steering Committee Meeting  
By Invitation
The BMT Pharmacists Conference is held annually in conjunction with the BMT Tandem Meetings. During the two-day conference, multiple pharmacy leaders specializing in HCT and experts from other disciplines provide perspective in the clinical management of this complex patient population using an evidence-based approach.

Syntaxx Communications, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Syntaxx Communications has assigned 12.5 contact hours (1.25 CEUs) of continuing pharmacy education credit for this knowledge- and application-based activity. This two-day live conference will incorporate 13 individual activity sessions that combined will fulfill the 12.25 hours of CE. The target audience for this accredited activity is pharmacists. To receive continuing pharmacy education credit for the Conference, participants must attend the sessions in their entirety and complete the associated program evaluation forms.

Additionally, all US-based pharmacists must supply their National Association of Boards of Pharmacy (NABP) electronic Profile Identification (ePID) number and their birth month and day (MM/DD). No credit can or will be issued without this information. To acquire an NABP ePID, go to http://www.nabp.net and click on CPE Monitor. Universal Activity Numbers: 0299-9999-17-001-L01-P through 0299-9999-17-013-L01-P. For questions or issues related to continuing pharmacy education, please contact Syntaxx Communications: jmarino@syntaxxcomm.com.

Supported by educational grants from Chimerix, Inc. and Pharmacyclics.

Friday, February 24

Osceola A

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

8:15 am – 8:30 am
Welcome and Overview
 Kamakshi V. Rao, PharmD
8:30 am – 9:00 am
BMT Pharmacists Special Interest Group Update
  *Alison M. Gulbis, PharmD*

9:00 am – 10:15 am
American Society of Hematology Update
  *Karen Sweiss*

10:15 am – 10:30 am – Break

10:30 am – 11:30 am
Thrombotic Microangiopathy in HCT
  *Sonata Jodele, MD*

11:30 am – Noon
Challenging Cases – Management of HLH
  *Karissa Kusick Dominick, PharmD, BCOP*

Noon – 1:15 pm – Lunch Buffet
Osceola Lobby

1:15 pm – 2:30 pm
New Drug Update
  *Laura Kay Whited, PharmD, BCOP*

2:30 pm – 2:45 pm – Break

2:45 pm – 4:00 pm
Best Pharmacy Abstracts

  IV Posaconazole in Pediatric HCT
    *Ashley Teusink-Cross, PharmD, MBA, BCPS*

  Olanzapine for CINV Prevention in Auto HCT
    *Theresa A. Nerone, PharmD*

  Efficacy of Afternoon Plerixafor Administration Mobilization
    *Cynthia Elrabi, PharmD*

  Influence of Body Weight on Melphalan Dosing in Auto HCT
    *Kendall Shultes, PharmD*

4:00 pm – 5:00 pm
Antimicrobial Stewardship
  *Kelly E. Pillinger, PharmD*

5:00 pm – 6:00 pm
BMT Pharmacists Networking Reception
St. Augustine: Castillo de San Marcos Fort – Upper Level
Saturday, February 25

Osceola A

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

8:15 am – 8:30 am
Welcome and Overview
Colleen Timlin, PharmD

8:30 am – 9:30 am
Pulmonary Complications of Transplant
Alex Ganetsky, PharmD, BCOP

9:30 am – 10:00 am
Challenging Cases – HCT in CNS Lymphoma
Anthony J. Proli, PharmD, BCOP, BCPS

10:00 am – 10:15 am – Break

10:15 am – 11:15 am
Early MRD/Relapse in AML
Marcos de Lima, MD

11:15 am – Noon
Award Presentations

Noon – 1:15 pm – Lunch Buffet
Osceola Lobby

1:15 pm – 2:15 pm
Hepatitis C in HCT Patients
Harrys A. Torres, MD

2:15 pm – 2:30 pm – Break

2:30 pm – 3:30 pm
GVHD Update
Elizabeth DiMaggio, PharmD, BCOP

3:30 pm – 4:45 pm
Best Practices in Stem Cell Mobilization
Kathy Hogan Edwards, PharmD, BCPS, BCOP,
Amber Diaz, PharmD, BCOP and
Philip Lubanski, PharmD

5:00 pm – 6:00 pm
BMT Pharmacist Conference Planning Meeting
for 2018
By Invitation
The Transplant Nursing Conference will provide current updates and evidence-based practice to improve the quality of care for patients experiencing a BMT. Presentations from multidisciplinary leaders in nursing, medicine and supportive care will address issues that are relevant to nurses and others caring for this patient population, such as symptom management, indications for treatment, patient and family issues, systems related issues and much more. There will be many opportunities for networking and learning what colleagues around the world are doing in practice through oral abstract presentations and the round table sessions.

Registered attendees can earn 17.5 CNE if all educational sessions are attended in their entirety.

The Oncology Nursing Society (ONS) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC’s) Commission on Accreditation. ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Nurses can earn up to an additional 3.0 CNE for viewing the poster abstracts on their own time. For every 19 posters viewed an additional 1.0 CNE can be earned.

Wednesday, February 22
6:00 pm – 8:00 pm
Drop-In Meet and Greet for First-Time Transplant Nursing Conference Attendees
St. George #114
Thursday, February 23

Osceola D

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

8:30 am – 8:45 am
Welcome
  Rebecca Martin, BSN, RN, OCN, BMTCN and
  Mary E. Peterson, MS, APRN, AOCNP

8:45 am – 10:00 am
Transfusion-Free Transplant
(Bloodless Autologous Stem Cell Transplant)
  Cassandra Upchurch, BSN, RN

10:00 am – 10:30 am – Break

10:30 am – Noon
Dermatologic Issues in Acute GVHD
  Amin M. Alousi, MD,
  Joyce L. Neumann, PhD, APRN, AOCN, BMTCN and
  Sharon R. Hymes, MD

Noon – 1:15 pm – Lunch Buffet
Osceola Lobby

1:15 pm – 2:15 pm
Transplant Nursing Best Abstracts
Supported by ONS Foundation

  Development of and Compliance with a Vitamin D Monitoring and Supplementation Program for Hematopoietic Stem Cell Transplant Patients
  Karen Collum, DNP, RN, OCN

  Effect of Increased Activity on Deconditioning in Pediatric Stem Cell Transplant Patients: A Feasibility Study
  Heather Marie Taylor, RN, BSN, CPHON

2:15 pm – 2:45 pm – Break

2:45 pm – 4:00 pm
Ethics and BMT Nursing – Medical Ethics for Transplant Nurses: A Case-Based Discussion
  Mary Victoria Weise, RN, BSN, OCN

Supported by ONS Foundation

4:00 pm – 5:15 pm
BMT Emergencies
  Juan Pinelli, PA-C, MMSc
Friday, February 24

Osceola D

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

8:30 am – 10:00 am
Hot Topics – They Transplant for That?
George E. Georges, MD and
Bernadette McLaughlin, BSN, RN

10:00 am – 10:30 am – Break

10:30 am – Noon
Transplant Nursing Roundtables

Noon – 1:15 pm – Lunch Buffet
Osceola Lobby

1:15 pm – 2:15 pm
Transplant Nursing Oral Abstracts

Calcineurin-Inhibitor Free Graft-Versus-Host Disease Prophylaxis: Its Effects on Magnesium, Renal Function, and the Cost of Care
Marlee Muilenburg, RN, BSN

Coping with Moderate and Severe Chronic Graft-Versus-Host Disease
Jessica P. Driscoll, DNP, ANP-BC

BMTCN® Yes You Can!
Amy Patterson, MSN, RN, AOCNS, BMTCN

2:15 pm – 2:45 pm – Break

2:45 pm – 4:00 pm
Immunotherapy and the Role of CAR-T – Cellular Immunotherapies – Going Beyond Hematopoietic Cell Transplants
Parameswaran N. Hari, MD, MS

4:00 pm – 5:00 pm
Transplant Nursing Special Interest Group Steering Committee Meeting
Osceola D
Saturday, February 25

Osceola D

6:30 am – 8:15 am – Continental Breakfast Buffet
Exhibit Hall F

8:30 am – 10:00 am
AYA Considerations/Programs
  Kyrie Hospodar Magee, CPNP, MSN, RN and
  Kristen L. Beebe, PA-C

10:00 am – 10:30 am – Break

10:30 am – Noon
Reproductive Issues in Transplant
  Brooke Cherven, RN, MPH, CPON

Noon – 1:15 pm – Lunch Buffet
Osceola Lobby

1:15 pm – 2:15 pm
Transplant Nursing Oral Abstracts

  Bone Marrow Transplant (BMT) Inpatient
  Discharge Education: Structured Problem Solving
    Chelsea Harding, BSN, RN, OCN

  Assessing Needs and Concerns of Autologous and
  Allogeneic Stem Cell Transplant Survivors at 1-5
  Years: A Quality of Life Approach
    Lauren E. Brister, NP-C, AOCNP

  Not All Positive Cultures are Bad:
  Improving Work Culture on the PBMT Unit
    Kristen Ammon, MSN, RN

2:15 pm – 2:45 pm – Break

2:45 pm – 3:45 pm
Fresh Outlook Session
Learn about the new or unique ways your peers are solving
problems in their own practice. Prior to the Poster Session
join fellow attendees for moderated discussion to examine
how to implement new ideas into your own practice.

4:00 pm – 6:00 pm
Transplant Nursing Conference Planning Team Meeting
for 2018
Sun 1
By Invitation
2016-2017 ASBMT Committees

Many special thanks to the volunteer committee members whose work directs the future of the Society:

Committee on Cellular Therapy

Chairs: Helen E. Heslop, MD
       Marcel R.M. van den Brink, MD, PhD

Members: A. John Barrett, MD
        Catherine M. Bollard, MD
        Colleen Delaney, MD, MSc
        Ardesbir Ghavamzadeh, MD
        Saar I. Gill, MD, PhD
        Jonathan A. Gutman, MD
        Aisha N. Hasan, MD
        Peiman Hematti, MD
        Edwin Horwitz, MD
        Saad S. Kenderian, MD
        Marcela V. Maus, MD, PhD
        Robert Negrin, MD
        Marcelo C. Pasquini, MD, MS
        Asha B. Pillai, MD
        Jerome Ritz, MD
        Elizabeth J. Shpall, MD
        Jakub Tolar, MD, PhD

Committee on Education

Chairs: Mark R. Litzow, MD
       Miguel-Angel Perales, MD

Members: Sita D. Bhella, MD
        Melissa A. Cochran, RN, NP
        Luciano J. Costa, MD, PhD
        Zachariah M. DeFilipp, MD
        Michael W. Kent, MD
        Shakila P. Khan, MD
        Tippu S. Khan, PharmD
        Andreas K. Klein, MD
        Amrita Y. Krishnan, MD
        Adriana K. Malone, MD
        Muhammad A. Mir, MD
        Carina G. K. Moravec, ARNP
        George B. Selby, MD
        Melisa K. Stricherz, PharmD
        D. Kathryin Tierney, RN, PhD
        Auro Viswabandya, MD
        William A. Wood, MD, MPH
Committee on Education:
Subcommittee on Web-Based Learning

Chair: William A. Wood, MD, MPH
Members: Melissa A. Cochran, RN, NP
Luciano J. Costa, MD, PhD
Tippu S. Khan, PharmD
Andreas K. Klein, MD
Mark R. Litzow, MD
Miguel-Angel Perales, MD

Committee on Practice Guidelines

Chairs: Paul A. Carpenter, MD
Bipin N. Savani, MD
Members: Eric Chow, PharmD
Peter T. Curtin, MD
Zachariah M. DeFilipp, MD
Suzanne R. Fanning, DO
Mehdi Hamadani, MD
Betty K. Hamilton, MD
Shahrukh K. Hashmi, MD, MPH
Yoshi Inamoto, MD
Laura J. Johnston, MD
Everett Meyer, MD, PhD
Mohamad Mobty, MD, PhD
Arnon Nagler, MD, MSc
Mohamed A. Kharfan-Dabaja, MD
Jeanne M. Palmer, MD, MS
Miguel-Angel Perales MD
Joseph A. Pidala, MD, MS
J. Douglas Rizzo, MD, MS
Cesar Rodriguez Valdes, MD
Jeffrey R. Schriber, MD
Nina D. Shab, MD
Paul J. Shaughnessy, MD
John R. Wingard, MD
Committee on Quality Outcomes

Chairs: Roy B. Jones, MD, PhD
       Navneet S. Majhail, MD, MS

Members: Peggy L. Appel, MHA
          Javier Bolanos-Meade, MD
          Sara Close, PA-C
          Sarah A. Cooley, MD, ex-officio
          Helen E. Heslop, MD
          Madan H. Jagasia, MD
          Mark B. Juckett, MD
          C. Fred LeMaistre, MD
          Leslie S. Parran, RN
          Michael A. Pulsipher, MD
          J. Douglas Rizzo, MD, MS
          Helen E. Thormann, APN

Committee on Quality Outcomes:
Subcommittee on Informatics

Chairs: Roy B. Jones, MD, PhD
       Charles Martinez, BS
       Sarah A. Cooley, MD

Members: Matthew J. Kastigar, MBA
          Thomas R. Klumpp, MD
          Marcia Latiff
          Martin Maiers, BA
          David Patton, PA-C, MPAS
          Jane Pollack
          Dianne M. Reeves, CFRE
          Ramona T. Repaczki-Jones, MSE
          J. Douglas Rizzo, MD, MS
          Keith Stockerl-Goldstein, MD
          Richard Vinesett

Committee on RFI

Chair: Patrick J. Stiff, MD
Vice Chair: Kent H. Walters, MBA

Members: Stephanie A. Farnia, MPH
          Thomas R. Klumpp, MD
          C. Fred LeMaistre, MD
          Navneet S. Majhail, MD, MS
          Michael I. Rabin, MBA, MPA
          J. Douglas Rizzo, MD, MS
          William P. Vaughan, MD
ASBMT Special Interest Groups

Steering Committee of the BMT Center
Administrative Directors Special Interest Group
Chair: Tonya P. Cox, BSN, RN, OCN
Members: Clint L. Divine, MBA, MSM
Myrlena Lee, MBA
Leslie S. Parran, RN, MS, AOCN, NE-BC
Kent H. Walters, MBA
Vandana Rangnekar (Affiliate Member)

Steering Committee of the Cord Blood
Special Interest Group
Chairs: Juliet N. Barker, MBBS
Elizabeth J. Shpall, MD
Members: Joanne Kurtzberg, MD
Claudio Brunstein, MD, PhD
Colleen Delaney, MD, MSc

Steering Committee of the HCT
Survivorship Special Interest Group
Chairs: Shahrub K. Hashmi, MD, MPH
Linda J. Burns, MD
Members: New Committee – Members TBD

Steering Committee of the HCT Value and Health Economics Special Interest Group
Chairs: Richard T. Maziarz, MD
Linda J. Burns, MD
Members: Rocky Billups, MS
Gregory A. Yanik, MD
Guillermo J. Ruiz-Argüelles, MD
Theresa E. Hahn, PhD
Dave Vanness, Consultant

Steering Committee of the NP/PA
Special Interest Group
Chair: Jackie V. Dioguardi, MSHS, PA-C
Heather M. Hylton, PA-C, Chair-Elect
Susan M. Ferrey, PA-C, Outgoing Chair
Members: Brenda L. Frye, PA-C, DHSc
Randi Hoffman, PhD, RN
Amy Joyce, MSN, NP, AOCN
Carina G.K. Moravec, ARNP
Pamela Paplham, DNP, AOCNP, FNP-BC
Nancy Shreve, APN, FNP-BC
Julie E. Wilhauk, DNP, AOCNP, FNP-BC
Steering Committee of the Palliative Care Special Interest Group
Chairs: Effie Petersdorf, MD
       Thomas W. LeBlanc, MD, MA
Members: New Committee – Members TBD

Steering Committee of the Pediatric Special Interest Group
Chair: Michael A. Pulsipher, MD
Members: Carl Allen, MD
         Jeffrey J. Auletta, MD
         K. Scott Baker, MD, MS
         Terry J. Frey, MD
         Steven A. Grupp, MD, PhD
         Alex Y. Huang, MD, PhD
         Carrie L. Kitko, MD
         John E. Levine, MD, MS
         Franco Locatelli, MD
         Rebecca A. Marsh, MD
         Margaret L. MacMillan, MD, MSc
         Julie M. Talano, MD
         Michael R. Verneris, MD
         Paul Veys, MBBS
         Gregory A. Yanik, MD

Steering Committee of the Pharmacy Special Interest Group
Chair: Alison M. Gulbis, PharmD
Members: Tippu S. Khan, PharmD
         Joseph S. Bubalo, PharmD
         Jeffrey A. Butcher, PharmD
         Amber B. Clemmons, PharmD, BCOP
         Alex Ganetsky, PharmD
         LeAnne D. Kennedy, PharmD

Steering Committee of the Transplant Infectious Diseases Special Interest Group
Chairs: Roy F. Chemaly, MD, MPH
       Michael J. Boeckh, MD, PhD
Members: Aliyah Baluch, MD, MSc
         Kieren A. Marr, MD
         Janet A. Englund, MD
         Ella J. Ariza-Heredia, MD
         Sherif B. Mossad, MD
Steering Committee of the Transplant Nursing Special Interest Group

Chair: Chris Rimkus, RN, MSN
Members: Margaret Bellerjeau, RN, MSN, OCN, CHTC
Suni D. Elgar, RN
Jennifer B. Frith, RN, BSN, OCN
Rebecca Gonzales, RN, BS, MA
Stephanie Jardine, RN, MSN
Elizabeth Murphy, EdD, RN, ex-officio
Joyce L. Neumann, PhD, APRN, AOCN, BMTCN
Lisa Pinner, RN, MSN, CPON, BMTCN
D. Kathryn Tierney, RN, PhD, ex-officio
CIBMTR Working Committee Meetings Schedule-at-a-Glance

The Medical College of Wisconsin designates this live activity for a maximum of **14.0 AMA PRA Category 1 Credit™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Wednesday, February 22**

**12:15 pm – 2:15 pm**  
**Plasma Cell Disorders and Adult Solid Tumors**  
Naples 1-3

**12:15 pm – 4:45 pm**  
**Immunobiology**  
Osceola 1-3

**2:45 pm – 4:45 pm**  
**Late Effects and Quality of Life**  
Naples 1-3

**2:45 pm – 4:45 pm**  
**Primary Immune Deficiencies, Inborn Errors of Metabolism and Other Non-Malignant Marrow Disorders**  
Osceola 4-6

**Thursday, February 23**

**12:15 pm – 2:15 pm**  
**Acute Leukemia**  
Osceola 4-6

**12:15 pm – 2:15 pm**  
**Autoimmune Diseases and Cellular Therapies**  
Osceola 1-3

**2:45 pm – 4:45 pm**  
**Graft Sources and Manipulation**  
Osceola 4-6

**2:45 pm – 4:45 pm**  
**Lymphoma**  
Osceola 1-3
Friday, February 24

12:15 pm – 2:15 pm
Graft-Versus-Host Disease
Osceola 4-6
Supported by a grant from Gilead Sciences, Inc.

12:15 pm – 2:15 pm
Health Services and International Studies
Osceola 1-3

12:15 pm – 2:15 pm
Regimen-Related Toxicity
Naples 1-3

Saturday, February 25

12:15 pm – 2:15 pm
Infection and Immune Reconstitution
Osceola 1-3
Supported by a grant from Astella Pharma US, Inc.

12:15 pm – 2:15 pm
Pediatric Cancer
Osceola 4-6

2:45 pm – 4:45 pm
Chronic Leukemia
Osceola 1-3

2:45 pm – 4:45 pm
Donor Health and Safety
Naples 1-3
CIBMTR Working Committee
Leadership and Staff

Acute Leukemia
Chairs: Marcos J.G. de Lima, MD
       Brenda M. Sandmaier, MD
       Hanna J. Khoury, MD
Scientific Director: Daniel J. Weisdorf, MD
Assistant Scientific Director: Wael Saber, MD, MS
Statistical Director: Mei-Jie Zhang, PhD
Statistician: Hailin Wang, MPH

Autoimmune Diseases and Cellular Therapies
Chairs: Ian Lewis, MBBS, PhD
       David McKenna, MD
       Stefanie Sarantopoulos, MD, PhD
Scientific Director: Marcelo C. Pasquini, MD, MS
Statistical Director: Ruta Brazauskas, PhD
Statistician: Kyle Bo-Subait, MPH

Chronic Leukemia
Chairs: Edwin Alyea, MD
       Uday R. Popat, MD
       Ronald Sobecks, MD
Scientific Director: Wael Saber, MD, MS
Statistical Directors: Kwang Woo Ahn, PhD
                    Ying Liu, PhD
Statistician: Zhenhuan Hu, MPH

Donor Health and Safety
Chairs: Galen E. Switzer, PhD
       Michael A. Pulsipher, MD
       Niral Shah, MD, MHSce
Scientific Director: Bronwen E. Shaw, MD, PhD
Associate Scientific Director: Dennis L. Confer, MD
Statistical Director: Brent R. Logan, PhD
Statisticians: Deidre Kiefer, MPH
              Pintip Chitphakdithai, PhD
CAC Representatives: Maureen Beamen
                     Beatrice Abetti, MSW, LCSW
                     Jeffrey Haertling

Graft Sources and Manipulation
Chairs: Miguel-Angel Perales, MD
       Vanderson Rocha, MD, PhD
       Asad Bashey, MD, PhD
Scientific Director: Mary Eapen, MD, MS
Statistical Director: Mei-Jie Zhang, PhD
Statistician: Andrew St. Martin, MS
Graft-Versus-Host Disease
Chairs: Daniel R. Couriel, MD, MS
Amin M. Alousi, MD
Joseph A. Pidala, MD, PhD
Scientific Directors: Mukta Arora, MD, MS
Stephen R. Spellman, MBS
Statistical Directors: Tao Wang, PhD
Ying Liu, PhD
Statistician: Michael Hemmer, MS
CAC Representatives: Hilary N. Hall
Jim Omel, MD

Health Services and International Studies
Chairs: Carmem M. Sales-Bonfim, MD
Jignesh Dalal, MD
Theresa E. Habn, PhD
Nandita Kbera, MD
Scientific Director: Wael Saber, MD, MS
Statistical Director: Ruta Brazauskas, PhD
Statistician: Naya He, MPH
CAC Representatives: Gerardo Camarillo, JD
Jack Aiello

Immunobiology
Chairs: Michael R. Verneris, MD
Katharina Fleischbauer, MD
Katharine Hsu, MD, PhD
Scientific Directors: Stephanie J. Lee, MD, MPH
Stephen R. Spellman, MBS
Statistical Director: Tao Wang, PhD
Statistician: Michael Haagenson, MS

Infection and Immune Reconstitution
Chairs: Jeffery Auletta, MD
Caroline A. Lindemans, MD, PhD
Krishna V. Komanduri, MD
Scientific Director: Marcie L. Riches, MD, MS
Statistical Director: Soyoung Kim, PhD
Statistician: Min Chen, MS

Late Effects and Quality of Life
Chairs: Bipin N. Savani, MD
Mary E.D. Flowers, MD
Minoo Battiwalla, MD, MS
Scientific Director: Bronwen E. Shave, MD, PhD
Statistical Director: Ruta Brazauskas, PhD
Statistician: Heather Millard, MPH
CAC Representatives: Kristen Scheeler
Barry Schatz
Lymphoma

Chairs: Sonali Smith, MD
       Anna Sureda, MD
       Timothy S. Fenske, MD, MS

Scientific Director: Mehdi Hamadani, MD
Statistical Director: Kwang Woo Ahn, PhD
Statistician: Alyssa DiGilio, MS

Pediatric Cancer

Chairs: Gregory Hale, MD
       Parinda Mehta, MD
       Angela Smith, MD, MS

Scientific Director: Mary Eapen, MD, MS
Statistical Director: Kwang Woo Ahn, PhD
Statistician: Heather Millard, MPH

Plasma Cell Disorders and Adult Solid Tumors

Chairs: Amrita Y. Krishnan, MD, FACP
       Cristina Gasparetto, MD
       Yago Neito, MD, PhD
       Tomer Mark, MD

Scientific Director: Parameswaran N. Hari, MD, MS
Assistant Scientific Director: Anita D'Souza, MD, MS
Statistical Director: Raphael Fraser, PhD
Statistician: Omar Davila, MPH
CAC Representative: Jim Omel, MD

Primary Immune Deficiencies, Inborn Errors of Metabolism and Other Non-Malignant Marrow Disorders

Chairs: Paolo Anderlini, MD
       Neena Kapoor, MD
       Jaap-Jan Boelens, MD, PhD
       Vikram Mathews, MD

Scientific Director: Mary Eapen, MD, MS
Statistical Director: Soyoung Kim, PhD
Statistician: Kyle Hebert, MS

Regimen-Related Toxicity and Supportive Care

Chairs: Andrew S. Artz, MD, MS
       Alison W. Loren, MD, MS
       Shin Mineishi, MD

Scientific Director: Marcelo C. Pasquini, MD, MS
Statistical Director: Brent R. Logan, PhD
Statistician: Xiaochun Zhu, MS
Invited Faculty
BMT Tandem Scientific Meeting

Tobias Alexander, MD
Charite-Universitätsmedizin Berlin
Berlin, Germany

Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, MA

Joseph H. Antin, MD
Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA

Andrew S. Artz, MD, MS
University of Chicago School of Medicine
Chicago, IL

David E. Avigan, MD
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, MA

Veronika Bachanova, MD, PhD
University of Minnesota
Minneapolis, MN

Juliet N. Barker, MBBS
Memorial Sloan Kettering Cancer Center
New York, NY

Minoo Battiwalla, MD, MS
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, MD

Bruce R. Blazar, MD
University of Minnesota
Minneapolis, MN

Michael J. Boeckh, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Michael Boo, JD
National Marrow Donor Program/Be The Match
Minneapolis, MN

Linda J. Burns, MD
National Marrow Donor Program/Be The Match
Minneapolis, MN
Jose F. Camargo, MD  
University of Miami, Miller School of Medicine  
Miami, FL

Richard E. Champlin, MD  
UT MD Anderson Cancer Center  
Houston, TX

Robert Chen, MD  
City of Hope National Medical Center  
Duarte, CA

Kenneth R. Cooke, MD  
Johns Hopkins Kimmel Cancer Center  
Baltimore, MD

Luciano J. Costa, MD, PhD  
University of Alabama  
Birmingham, AL

Corey S. Cutler, MD, MPH  
Dana-Farber Cancer Institute  
Boston, MA

H. Joachim Deeg, MD  
Fred Hutchinson Cancer Research Center  
Seattle, WA

Steven M. Devine, MD  
The Ohio State University Comprehensive Cancer Center  
Columbus, OH

John F. DiPersio, MD, PhD  
Washington University School of Medicine  
St. Louis, MO

Peter Dreger, MD, PhD  
University Hospital  
Heidelberg, Germany

Hermann Einsele, MD  
Universitätsklinikum Würzburg  
Würzburg, Germany

Areej R. El-Jawahri, MD  
Massachusetts General Hospital  
Boston, MA

Stephanie A. Farnia, MPH  
ASBMT  
Arlington Heights, IL

Timothy S. Fenske, MD, MS  
Medical College of Wisconsin  
Milwaukee, WI

James Ferrara, MD, DSc  
Icahn School of Medicine at Mount Sinai  
New York, NY
Saar I. Gill, MD, PhD
University of Pennsylvania
Philadelphia, PA

Sergio A. Giralt, MD
Memorial Sloan Kettering Cancer Center
New York, NY

David Gómez-Almaguer, MD
Universidad Autonoma de Nuevo Leon
Monterrey, Mexico

Ted Alan Gooley, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA

Stephan A. Grupp, MD, PhD
The Children’s Hospital of Philadelphia
Philadelphia, PA

Vikas Gupta, MD
Princess Margaret Cancer Center
Toronto, Canada

Mehdi Hamadani, MD
Medical College of Wisconsin
Milwaukee, WI

Alan M. Hanash, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Parameswaran N. Hari, MD, MS
Medical College of Wisconsin
Milwaukee, WI

Helen E. Heslop, MD
Baylor College of Medicine
Houston, TX

Ernst Holler, MD, PhD
University of Regensburg
Regensburg, Germany

Richard J. Jones, MD
Johns Hopkins University School of Medicine
Baltimore, MD

Christopher G. Kanakry, MD
National Cancer Institute, National Institutes of Health
Bethesda, MD

Partow Kebriaei, MD
UT MD Anderson Cancer Center
Houston, TX
Brent R. Logan, PhD  
Medical College of Wisconsin  
Milwaukee, WI

Leo Luznik, MD  
Johns Hopkins University School of Medicine  
Baltimore, MD

Margaret L. MacMillan, MD, MSc  
University of Minnesota  
Minneapolis, MN

Navneet S. Majhail, MD, MS  
Cleveland Clinic Taussig Cancer Institute  
Cleveland, OH

David I. Marks, MBBS, PhD  
University Hospitals Bristol NHS Trust  
Bristol, United Kingdom

Rebecca A. Marsh, MD  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

Everett Meyer, MD, PhD  
Stanford University  
Stanford, CA

David Miklos, MD, PhD  
Stanford University  
Stanford, CA

Erica C. Moodie, PhD  
McGill University  
Montreal, Canada

Emma C. Morris, MD, PhD  
University College London  
London, United Kingdom

Robert Negrin, MD  
Stanford University  
Stanford, CA

Nicolas Novitzky, MD, PhD  
University of Cape Town Medical School  
Cape Town, South Africa

Richard J. O’Reilly, MD  
Memorial Sloan Kettering Cancer Center  
New York, NY

Sophie Paczesny, MD, PhD  
Indiana University  
Indianapolis, IN
Marcelo C. Pasquini, MD, MS
CIBMTR and Medical College of Wisconsin
Milwaukee, WI

Effie Petersdorf, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Jerome Ritz, MD
Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA

Rizwan Romee, MD
Washington University School of Medicine
St. Louis, MO

Ashley Rosko, MD
Ohio State University
Columbus, OH

Montserrat Rovira, MD, PhD
Hospital Clinic
Barcelona, Spain

Guillermo J. Ruiz-Argüelles, MD
Clinica Ruiz
Puebla, Mexico

Brenda M. Sandmaier, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Craig S. Sauter, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Bart L. Scott, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Bronwen E. Shaw, MD, PhD
CIBMTR and Medical College of Wisconsin
Milwaukee, WI

Thomas C. Shea, MD
University of North Carolina
Chapel Hill, NC

John A. Snowden, MD
Sheffield Teaching Hospitals
Sheffield, United Kingdom

Robert J. Soiffer, MD
Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA
Matthew Spitzer, PhD
University of California, San Francisco
San Francisco, CA

Alok Srivastava, MD
Christian Medical College
Vellore, India

Rainer Storb, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Jeffrey Szer, MBBS
Royal Melbourne Hospital
Parkville, Australia

André Tichelli, MD
University Hospital Basel
Basel, Switzerland

Laurel Todd, MBA
Biotechnology Innovation Organization
Washington, DC

Christina Ullrich, MD, MPH
Boston Children’s Hospital/Dana-Farber Cancer Institute
Boston, MA

Luca Vago, MD, PhD
San Raffaele Scientific Institute
Milano, Italy

Marcel R.M. van den Brink, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Jeremy Walston, MD
Johns Hopkins University School of Medicine
Baltimore, MD

Kent H. Walters, MBA
UT MD Anderson Cancer Center
Houston, TX

Daniel J. Weisdorf, MD
University of Minnesota
Minneapolis, MN

Peter Westervelt, MD, PhD
Washington University School of Medicine
St. Louis, MO

John R. Wingard, MD
University of Florida
Gainesville, FL
Catherine Wu, MD  
Dana-Farber Cancer Institute  
Boston, MA

Anas Younes, MD  
Memorial Sloan Kettering Cancer Center  
New York, NY

Invited Faculty  
Pediatric BMT Program

Carl Allen, MD  
Baylor College of Medicine, Texas Children’s Hospital  
Houston, TX

Christopher Bredeson, MD, MSc  
The Ottawa Hospital, University of Ottawa  
Ottawa, Canada

Andrew C. Dietz, MD, MSCR  
Children’s Hospital Los Angeles  
Los Angeles, CA

Stephanie A. Farnia, MPH  
ASBMT  
Arlington Heights, IL

Terry Fry, MD  
National Cancer Institute, National Institutes of Health  
Bethesda, MD

Cynthia A. Gerhardt, PhD  
The Research Institute at Nationwide Children’s Hospital  
Columbus, OH

Elie Haddad, MD, PhD  
Ste-Justine Hospital  
Montreal, Canada

Alex Huang, MD, PhD  
Case Western Reserve University  
Cleveland, OH

Sonata Jodele, MD  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

Carrie L. Kitko, MD  
Vanderbilt University Medical Center  
Nashville, TN
John Letterio, MD
University Hospital Cleveland Medical Center and
Case Western Reserve University
Cleveland, OH

Margaret L. MacMillan, MD, MSc
University of Minnesota
Minneapolis, MN

Ivan Maillard, MD, PhD
University of Michigan
Ann Arbor, MI

Rebecca A. Marsh, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Booki Min, PhD
Cleveland Clinic
Cleveland, OH

Michael A. Pulsipher, MD
Children’s Hospital Los Angeles
Los Angeles, CA

Galen E. Switzer, PhD
University of Pittsburgh
Pittsburgh, PA

David T. Teachey, MD
Children’s Hospital of Philadelphia
Philadelphia, PA

Danielle Townsley, MD, MSc
National Heart, Lung and Blood Institute
National Institutes of Health
Bethesda, MD

Lucie Turcotte, MD
Masonic Cancer Center
Minneapolis, MN

Paul Veys, MBBS
Great Ormond Street Hospital for Children
London, United Kingdom

John E. Wagner, MD
University of Minnesota
Minneapolis, MN
Invited Faculty
Clinical Research Professionals/
Data Management Conference

Denise Bellman, CRC
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Erik Bergman, MBA, MS
CIBMTR/Medical College of Wisconsin
Milwaukee, WI

Ashley Birch
CIBMTR, NMDP/Be The Match
Minneapolis, MN

Cullen Case
CIBMTR, NMDP/Be The Match
Minneapolis, MN

Rebecca J. Drexler
CIBMTR, NMDP/Be The Match
Minneapolis, MN

Read Fritsch
CIBMTR, NMDP/Be The Match
Minneapolis, MN

Kay Gardner
CIBMTR, NMDP/Be The Match
Minneapolis, MN

Paul Gengler
CIBMTR/Medical College of Wisconsin
Milwaukee, WI

Mary M. Horowitz, MD, MS
CIBMTR and Medical College of Wisconsin
Milwaukee, WI

Emily Laskowski
University of Kansas
Kansas City, KS

Stephanie J. Lee, MD, MPH
Fred Hutchinson Cancer Research Center
Seattle, WA

Emilie Love
CIBMTR, NMDP/Be The Match
Minneapolis, MN

Sharon K. Meiers
CIBMTR/Medical College of Wisconsin
Milwaukee, WI
Jason Parmentier, BSN, RN  
Barnes Jewish Hospital  
St. Louis, MO

Mandi Proue  
CIBMTR, NMDP/Be The Match  
Minneapolis, MN

Marcie L. Riches, MD, MS  
University of North Carolina  
Chapel Hill, NC

J. Douglas Rizzo, MD, MS  
CIBMTR and Medical College of Wisconsin  
Milwaukee, WI

Elizabeth Roberts  
Cincinnati Children’s Hospital Medical Center  
Cincinnati, OH

Bronwen E. Shaw, MD, PhD  
CIBMTR and Medical College of Wisconsin  
Milwaukee, WI

Daniel Skolnick  
Massachusetts General Hospital  
Boston, MA

Bridget Wakaruk, SCM  
CIBMTR, NMDP/Be The Match  
Minneapolis, MN

Phyllis I. Warkentin, MD  
University of Nebraska Medical Center  
Omaha, NE

Daniel J. Weisdorf, MD  
University of Minnesota  
Minneapolis, MN

Jennifer R. Willert, MD  
Children’s Hospital San Diego  
San Diego, CA

Invited Faculty  
CRP/DM In-Depth Training

Andrea Benoit  
CIBMTR/Medical College of Wisconsin  
Milwaukee, WI
Janet Brunner-Grady, PA-C  
CIBMTR/Medical College of Wisconsin  
Milwaukee, WI  

Anita D’Souza, MD, MS  
Medical College of Wisconsin  
Milwaukee, WI  

Leigh Ann Laczkowski  
CIBMTR/Medical College of Wisconsin  
Milwaukee, WI  

Sue Logan, MS, CCRP  
CIBMTR, NMDP/Be The Match  
Minneapolis, MN  

Elliott Michem  
CIBMTR/Medical College of Wisconsin  
Milwaukee, WI  

Alisha Mussetter  
CIBMTR, NMDP/Be The Match  
Minneapolis, MN  

Tina Thole  
CIBMTR, NMDP/Be The Match  
Minneapolis, MN  

Invited Faculty  
BMT CTN Investigators Meeting  

Amin M. Alousi, MD  
UT MD Anderson Cancer Center  
Houston, TX  

Yi-Bin Chen, MD  
Massachusetts General Hospital  
Boston, MA  

Steven M. Devine, MD  
The Ohio State University Comprehensive Cancer Center  
Columbus, OH  

Stephanie J. Lee, MD, MPH  
Fred Hutchinson Cancer Research Center  
Seattle, WA  

Marcelo C. Pasquini, MD, MS  
CIBMTR and Medical College of Wisconsin  
Milwaukee, WI
Invited Faculty
BMT CTN Coordinators Meeting

**Brianne Allison**
The Emmes Corporation
Rockville, MD

**Jennifer Baker, RN**
Duke University Medical Center
Durham, NC

**Catherine M. Bollard, MD**
Children’s National Medical Center
Washington, DC

**Stacey Brown**
Northside Hospital Cancer Institute
Atlanta, GA

**Steven M. Devine, MD**
The Ohio State University Comprehensive Cancer Center
Columbus, OH

**Amy E. DeZern, MD, MHS**
Johns Hopkins University School of Medicine
Baltimore, MD

**Mary Eapen, MD, MS**
CIBMTR and Medical College of Wisconsin
Milwaukee, WI

**Amy Foley, MA, CCRP**
National Marrow Donor Program
Minneapolis, MN

**Iris D. Gersten, MS**
The Emmes Corporation
Rockville, MD

**Adetola Kassim, MD, MS**
Vanderbilt University Medical Center
Nashville, TN

**Denise King, MS**
The Emmes Corporation
Rockville, MD

**Roberta J. King, MPH**
CIBMTR, NMDP/Be The Match
Minneapolis, MN

**Kristin Knust, MS**
The Emmes Corporation
Rockville, MD
Philip L. McCarthy, MD
Roswell Park Cancer Institute
Buffalo, NY

Katie McCray
Ohio State University Medical Center
Columbus, OH

Adam Mendizabal, PhD
The Emmes Corporation
Rockville, MD

Lisa Murray, MA
Washington University
St. Louis, MO

Courtney Nelson
The Emmes Corporation
Rockville, MD

Ellen Parker, MBA
The Emmes Corporation
Rockville, MD

Marcelo C. Pasquini, MD, MS
CIBMTR and Medical College of Wisconsin
Milwaukee, WI

Terry Pritchard, MS
The Emmes Corporation
Rockville, MD

Whitney Reid
Weill Cornell University
New York, NY

Marcie L. Riches, MD, MS
University of North Carolina
Chapel Hill, NC

Nina D. Shah, MD
University of California
San Francisco, CA

Ashley Spahn
CIBMTR/National Marrow Donor Program
Minneapolis, MN

Audra Thompson, RN, BSN
The Emmes Corporation
Rockville, MD

Noah Tucker, CCRC
Johns Hopkins University School of Medicine
Baltimore, MD
Stephanie Waldvogel
CIBMTR/National Marrow Donor Program
Minneapolis, MN

Mark C. Walters, MD
Children’s Hospital of Oakland
Oakland, CA

Samantha Wilkins
The Emmes Corporation
Rockville, MD

Maggie Wu, MS
The Emmes Corporation
Rockville, MD

Invited Faculty
Administrative Directors Conference

Ruth Brentari, MHA
Kaiser Permanente
Oakland, CA

Jennifer A. Christian, CHTC
University of Kentucky Medical Center
Lexington, KY

Tonya P. Cox, BSN, RN, OCN
Sarah Cannon
Denver, CO

Clint L. Divine, MBA, MSM
University of Kansas Cancer Center
Westwood, KS

Therese Dodd, BA, MBA, RN, CPHQ, FNAHQ
Sarah Cannon
Nashville, TN

Stephanie A. Farnia, MPH
ASBMT
Arlington Heights, IL

Alex Ganetsky, PharmD, BCOP
University of Pennsylvania
Philadelphia, PA

Ryan Hillgruber
H. Lee Moffitt Cancer Center
Tampa, FL

Amanda K. Hrnicek, MBA, LBBA
Ohio State University, James Cancer Hospital
Columbus, OH
Partow Kebriaei, MD  
UT MD Anderson Cancer Center  
Houston, TX

Leslie S. Parran, RN, MS, AOCN, NE-BC, BMTCN  
University of Minnesota Medical Center  
Minneapolis, MN

J. Douglas Rizzo, MD, MS  
CIBMTR and Medical College of Wisconsin  
Milwaukee, WI

Jugna Shab, MPH  
Nimitt Consulting, Inc.  
Spicer, MN

S. Elizabeth Sharf, BSN, RN, NE-BC, CHTC  
University of North Carolina  
Chapel Hill, NC

Kent H. Walters, MBA  
UT MD Anderson Cancer Center  
Houston, TX

Invited Faculty

HCT Value and Health Economics Session

Linda J. Burns, MD  
National Marrow Donor Program/Be The Match  
Minneapolis, MN

David Dickens, MD  
Helen DeVos Children’s Hospital  
Grand Rapids, MI

Nathan J. Dowden  
Rubius Therapeutics  
Cambridge, MA

Kurt C. Gunter, MD  
Cell Medica  
Houston, TX

Lothar B. Huebsch, MD  
The Ottawa Hospital  
Ottawa, Canada

Richard T. Maziarz, MD  
Oregon Health & Science University  
Portland, OR
Vinay Prasad, MD, MPH  
Oregon Health & Science University  
Portland, OR

**Invited Faculty**  
**BMT Clinical Education Conference**  
(for NPs, PAs, Fellows and Junior Faculty)

**Allistair Abraham, MD**  
Children’s National Medical Center  
Washington, DC

**Claudio Anasetti, MD**  
H. Lee Moffitt Cancer Center and Research Institute  
Tampa, FL

**Sonali Chaudhury, MD**  
Lurie Children’s Hospital of Chicago  
Northwestern University  
Chicago, IL

**Sung Won Choi, MD**  
University of Michigan  
Ann Arbor, MI

**Aamer Chughtai, MD**  
University of Michigan  
Ann Arbor, MI

**Corey S. Cutler, MD, MPH**  
Dana-Farber Cancer Institute  
Boston, MA

**Zachariab M. DeFilipp, MD**  
Massachusetts General Hospital  
Boston, MA

**Jackie Dioguardi, PA-C**  
University of Michigan  
Ann Arbor, MI

**Areej R. El-Jawahri, MD**  
Dana-Farber Cancer Institute  
Boston, MA

**Robert Peter Gale, MD, PhD**  
Imperial College London  
London, United Kingdom

**Randi Hoffmann, PhD, RN, CNP**  
Medical University of South Carolina  
Charleston, SC
Angela Kirk, PA-C  
Seattle Cancer Care Alliance  
Seattle, WA

Benjamin Laskin, MD, MS  
The Children’s Hospital of Philadelphia  
Philadelphia, PA

Paula Charubas Macris, MS, RD, CSO  
Seattle Cancer Care Alliance  
Seattle, WA

Francisco M. Marty, MD  
Dana-Farber Cancer Institute  
Boston, MA

Lakshmi Nayak, MD  
Dana-Farber Cancer Institute  
Boston, MA

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN  
UT MD Anderson Cancer Center  
Houston, TX

Bart L. Scott, MD  
Fred Hutchinson Cancer Research Center  
Seattle, WA

Gregory A. Yanik, MD  
University of Michigan  
Ann Arbor, MI

Gabrielle Zecha, PA-C, MHA  
Fred Hutchinson Cancer Research Center  
Seattle, WA

Invited Faculty  
BMT Pharmacists Conference

Marcos de Lima, MD  
University Hospitals Seidman Cancer Center and  
Case Western Reserve University  
Cleveland, OH

Amber Diaz, PharmD, BCOP  
Oregon Health Sciences University  
Portland, OR

Elizabeth DiMaggio, PharmD, BCOP  
H. Lee Moffitt Cancer Center and Research Institute  
Tampa, FL
Kathy Hogan Edwards, PharmD, BCPS, BCOP
Medical University of South Carolina
Charleston, SC

Alex Ganetsky, PharmD, BCOP
University of Pennsylvania
Philadelphia, PA

Alison M. Gulbis, PharmD
UT MD Anderson Cancer Center
Houston, TX

Sonata Jodele, MD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Karissa Kusick Dominick, PharmD BCOP
Cleveland Clinic
Cleveland, OH

Philip Lubanski, PharmD
University of Kansas Hospital
Kansas City, KS

Kelly E. Pillinger, PharmD
Carolina’s Medical Center
Charlotte, NC

Anthony J. Proli, PharmD, BCOP, BCPS
Memorial Sloan Kettering Cancer Center
New York, NY

Kamaksbi V. Rao, PharmD
UNC Medical Center
Chapel Hill, NC

Karen Sweiss
University of Illinois at Chicago
Chicago, IL

Colleen Timlin, PharmD
University of Pennsylvania Health System
Philadelphia, PA

Harrys A. Torres, MD
UT MD Anderson Cancer Center
Houston, TX

Laura Kay Whited, PharmD, BCOP
MD Anderson Cancer Center
Houston, TX
Invited Faculty
Transplant Nursing Conference

Amin M. Alousi, MD
UT MD Anderson Cancer Center
Houston, TX

Kristen L. Beebe, PA-C
Phoenix Children’s Hospital
Phoenix, AZ

Brooke Cherven, RN, MPH, CPON
Children’s Healthcare of Atlanta
Atlanta, GA

George E. Georges, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

Parameswaran N. Hari, MD, MS
Medical College of Wisconsin
Milwaukee, WI

Sharon R. Hymes, MD
UT MD Anderson Cancer Center
Houston, TX

Kyrie Hospodar Magee, CPNP, MSN, RN
Phoenix Children’s Hospital/Mayo Clinic Arizona
Phoenix, AZ

Rebecca Martin, BSN, RN, OCN, BMTCN
Froedtert Hospital and The Medical College of Wisconsin
Milwaukee, WI

Bernadette McLaughlin, BSN, RN
Fred Hutchinson Cancer Research Center
Seattle, WA

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN
UT MD Anderson Cancer Center
Houston, TX

Mary E. Peterson, MS, APRN, AOCNP
Saint David’s South Austin Medical Center
Austin, TX

Juan Pinelli, PA-C, MMSc
Fred Hutchinson Cancer Research Center
Seattle, WA

Cassandra Upchurch, BSN, RN
Pennsylvania Hospital
Philadelphia, PA
Mary Victoria Weise, RN, BSN, OCN  
Mayo Clinic  
Phoenix, AZ

Invited Faculty  
Building a Patient-Centered Outcomes Research (PCOR) Collaborative Community

Beatrice Abetti, LCSW  
Leukemia & Lymphoma Society  
White Plains, NY

Staci Arnold, MD, MBA  
Columbia University  
New York, NY

Linda J. Burns, MD  
National Marrow Donor Program/Be The Match  
Minneapolis, MN

Ellen M. Denzen, MS  
National Marrow Donor Program/Be The Match  
Minneapolis, MN

Susan Doughtie, MS  
Georgia Cancer Center at Augusta University  
Augusta, GA

Rebecca J. Drexler  
CIBMTR, NMDP/Be The Match  
Minneapolis, MN

Areej R. El-Jawahri, MD  
Massachusetts General Hospital, Harvard Medical School  
Boston, MA

Mary M. Horowitz, MD, MS  
CIBMTR and Medical College of Wisconsin  
Milwaukee, WI

Mark B. Juckett, MD  
University of Wisconsin  
Madison, WI

Lakshmana Krishnamurti, MD  
Emory University  
Atlanta, GA

Alison W. Loren, MD, MSCE  
University of Pennsylvania  
Philadelphia, PA
Alva Roche-Green, MD
Mayo Clinic
Jacksonville, FL

Kim Schmit-Pokorny, RN, MSN, OCN, BMTCN
Nebraska Medicine
Omaha, NE

D. Kathryn Tierney, RN, PhD
Stanford Health Care
Stanford, CA

Christina Ullrich, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

William A. Wood, MD, MPH
University of North Carolina
Chapel Hill, NC
All Committee Meetings
Schedule-at-a-Glance

(For CIBMTR Working Committee information, please refer to pages 108-109).

2018 PLANNING MEETINGS

CRP/DM Conference Planning Meeting for 2018
By Invitation
Sun 2
Wednesday, February 22, 5:00 pm – 6:30 pm

BMT CTN Coordinators and Investigators Planning Meeting for 2018
By Invitation
Sun 1
Thursday, February 23, 8:30 am – 10:00 am

Pediatric BMT Program Planning Meeting for 2018
By Invitation
Sun 1
Friday, February 24, 7:00 am – 8:30 am

BMT Tandem Scientific Organizing Committee Meeting for 2018
By Invitation
Orange Blossom Ballroom
Saturday, February 25, 10:00 am – 11:30 am

Transplant Nursing Conference Planning Team Meeting for 2018
By Invitation
Sun 1
Saturday, February 25, 4:00 pm – 6:00 pm

BMT Pharmacists Conference Planning Committee Meeting for 2018
By Invitation
Osceola A
Saturday, February 25, 5:00 pm – 6:00 pm

Clinical Education Conference Planning Committee Meeting for 2018
By Invitation
Osceola C
Saturday, February 25, 5:30 pm – 6:30 pm
SUBCOMMITTEE/BUSINESS MEETINGS

PBMTC Business Meeting and Reception
Osceola A
Thursday, February 23, 6:15 pm – 7:00 pm

CIBMTR General Assembly
Florida Hall E
Friday, February 24, 2:45 pm – 3:00 pm

ASBMT Business Meeting
Open to All Attendees
Florida Hall E
Friday, February 24, 3:00 pm – 3:15 pm

ASBMT

ASBMT Committee on Cellular Therapy
By Invitation
St. George #112
Wednesday, February 22, 7:00 am – 8:00 am

ASBMT Committee on RFI
By Invitation
St. George #104
Wednesday, February 22, 7:30 am – 8:30 am

ASBMT Introduction/Orientation for Fellows-in-Training
Open to All Attendees
Sanibel 1-3
Wednesday, February 22, 10:00 am – 11:00 am

ASBMT Committee on Practice Guidelines
By Invitation
St. George #112
Wednesday, February 22, 6:45 pm – 7:45 pm

ASBMT Committee on Education
By Invitation
St. George #104
Thursday, February 23, 7:00 am – 8:30 am

ASBMT Palliative Care Special Interest Group
By Invitation
St. George #112
Thursday, February 23, 7:30 am – 8:30 am

ASBMT Past President’s Luncheon
By Invitation
St. George #112
Thursday, February 23, Noon – 1:30 pm
ASBMT Committee on Quality Outcomes  
By Invitation  
Emerald 1  
Thursday, February 23, 12:15 pm – 1:15 pm

ASBMT Survivorship Research and Special Interest Group Meeting  
By Invitation  
Orange Blossom Ballroom  
Thursday, February 23, 12:30 pm – 2:15 pm

ASBMT Sub-Committee on Informatics  
By Invitation  
Emerald 1  
Thursday, February 23, 1:15 pm – 2:15 pm

BBMT Editorial Board Meeting  
By Invitation  
St. George #106  
Thursday, February 23, 1:30 pm – 3:00 pm

ASBMT Choosing Wisely Task Force  
By Invitation  
Emerald 6  
Thursday, February 23, 2:00 pm – 3:00 pm

ASBMT Corporate Council Reception  
By Invitation  
Emerald Bay Plaza: Wedding Pavilion  
Thursday, February 23, 4:30 pm – 5:30 pm

ASBMT/CIBMTR/NMDP Leadership Meeting  
By Invitation  
St. George #106  
Friday, February 24, 7:00 am – 8:30 am

ASBMT Infectious Disease Special Interest Group Meeting  
Open to All Attendees  
Sun 4-6  
Friday, February 24, 7:00 am – 8:30 am

ASBMT Board of Directors Meeting  
By Invitation  
Orange Blossom Ballroom  
Friday, February 24, 10:30 am – 2:30 pm

Transplant Nursing Special Interest Group Steering Committee Meeting  
Open to All Attendees  
Osceola D  
Friday, February 24, 4:00 pm – 5:00 pm
ASBMT Special Interest Group Chair Meeting with President
By Invitation
St. George #104
Saturday, February 25, 7:30 am – 8:30 am

ASBMT Cord Blood Special Interest Group Meeting
Open to All Attendees
Tallahassee 1-3
Saturday, February 25, 12:15 pm – 2:15 pm

ASBMT Clinical Research Training Course Reunion
By Invitation
Emerald Bay Plaza: Wedding Pavilion
Saturday, February 25, 1:30 pm – 2:30 pm

ASBMT NP/PA Special Interest Group Business Meeting
Open to All Attendees
Osceola C
Saturday, February 25, 5:00 pm – 5:30 pm

CIBMTR

CIBMTR Advisory Committee Meeting
By Invitation
Osceola C
Wednesday, February 22, 12:15 pm – 4:15 pm

Cell Therapy Registry Pilot Center Update
Open to All Attendees
St. George #108
Wednesday, February 22, 5:00 pm – 6:30 pm

Statistical Consulting with CIBMTR PhD Biostatisticians
Open to All Attendees
Sarasota 1
Thursday, February 23, 10:30 am – Noon

International Data Managers Open Forum
Open to All Attendees
St. George #108
Thursday, February 23, 1:00 pm – 3:30 pm

CIBMTR Consumer Advocacy Committee Meeting
By Invitation
Emerald 6
Thursday, February 23, 4:45 pm – 6:15 pm

ASBMT/CIBMTR/NMDP Leadership Meeting
By Invitation
St. George #106
Friday, February 24, 7:00 am – 8:30 am
Statistical Consulting with CIBMTR PhD Biostatisticians
Open to All Attendees
Sarasota 1
Friday, February 24, 10:30 am – Noon

WBMT Board Meeting
By Invitation
Miami 1-3
Friday, February 24, 10:30 am – 1:30 pm

LABMT – Latin America Blood and Marrow Transplant Group
Open to All Attendees
Tallahassee 1-3
Friday, February 24, 6:45 pm – 8:45 pm

CIBMTR Mismatched Unrelated Donor (15-MMUD) Transplant PI/Coordinators Meetings
By Invitation
Sanibel 1-3
Saturday, February 25, 7:00 am – 8:30 am

CIBMTR Kepivance Study Protocol Team Meeting
By Invitation
St. George #106
Saturday, February 25, 7:30 am – 8:30 am

FACT

FACT Standards Kick-Off Meeting
By Invitation
Emerald 1
Monday, February 20, 7:00 am – 5:00 pm

FACT Cellular Therapy Inspection and Accreditation Workshop Applicant Track
Separate Registration Required
Tallahassee 1-3
Tuesday, February 21, 7:00 am – 5:00 pm

FACT Cellular Therapy Inspection and Accreditation Workshop Inspector Track
Separate Registration Required
Sanibel 1-3
Tuesday, February 21, 7:00 am – 5:00 pm

FACT Cellular Therapy Leadership Course 101
Separate Registration Required
Miami 1
Tuesday, February 21, 8:00 am – Noon
FACT Advanced Cellular Therapy Leadership Course 201
Separate Registration Required
Miami 1
Tuesday, February 21, 1:00 pm – 5:00 pm

FACT Board of Directors Meeting
By Invitation
Daytona 1-2
Tuesday, February 21, 6:00 pm – 10:00 pm

FACT ASBMT Quality Boot Camp
Open to All Attendees
Miami 1-3
Wednesday, February 22, 7:00 am – 5:00 pm

Introduction to the FACT Accreditation Portal
Open to All Attendees
Separate Registration Required
Daytona 1-2
Wednesday, February 22, 8:00 am – 10:00 am and
Wednesday, February 22, 2:30 pm – 4:30 pm

FACT Clinical Outcomes Committee Meeting
By Invitation
Daytona 1-2
Wednesday, February 22, 10:30 am – Noon

FACT Consultants Meeting
By Invitation
Daytona 1-2
Wednesday, February 22, Noon – 1:00 pm

FACT Consultants Board of Directors Meeting
By Invitation
Daytona 1-2
Wednesday, February 22, 1:00 pm – 2:00 pm

FACT Global Affairs:
Special Session for International Delegates
Open to All Attendees
Captiva 1-2
Wednesday, February 22, 5:00 pm – 7:00 pm

FACT Web Oversight Committee Meeting
By Invitation
Daytona 1-2
Wednesday, February 22, 6:45 pm – 8:00 pm

FACT CIBMTR Data Audit Meeting
By Invitation
Daytona 1-2
Thursday, February 23, 9:00 am – 10:30 am
FACT CAR T-Cell Task Force Meeting
By Invitation
Daytona 1-2
Thursday, February 23, 11:00 am – Noon

FACT Regenerative Medicine Task Force Meeting
By Invitation
Daytona 1-2
Thursday, February 23, Noon – 1:00 pm

Introduction to the FACT Accreditation Portal Day Two
Open to All Attendees
Separate Registration Required
Daytona 1-2
Thursday, February 23, 1:00 pm – 3:00 pm and
Thursday, February 23, 3:00 pm – 5:00 pm

Improving Clinical Outcomes with FACT Accreditation
Open to All Attendees
Sanibel 1-3
Friday, February 24, 7:30 am – 8:30 am

NMDP

BMT CTN Steering Committee Meeting
By Invitation
Osceola C
Tuesday, February 21, 8:30 am – 5:00 pm

Radiation Injury Treatment Network (RITN) Annual Update
Open to All Attendees
Sanibel 1-3
Wednesday, February 22, 7:00 am – 8:30 am

Transplant Late Effects in Children (TLEC) Investigators Meeting
By Invitation
Orange Blossom Ballroom
Wednesday, February 24, 7:00 am – 8:30 am

BMT CTN Myeloma Intergroup Meeting
By Invitation
Tallahassee 1-3
Wednesday, February 22, 6:45 pm – 8:45 pm

NMDP Transplant Center Networking Reception
Open to NMDP/Be The Match Network Transplant Centers Only
St. Augustine: Castillo de San Marcos Fort – Lower Level
Wednesday, February 22, 7:00 pm – 9:00 pm
Orientation to CIBMTR/BMT CTN
Open to All Attendees
Naples 1-3
Thursday, February 23, 7:00 am – 8:15 am

RCI BMT Clinical Trials Advisory Committee (CTAC) Meeting
By Invitation
Orange Blossom Ballroom
Thursday, February 23, 7:00 am – 8:30 am

BMT Data Standards and Interoperability
By Invitation
Sun 4-6
Thursday, February 23, 1:00 pm – 4:30 pm

ASBMT/CIBMTR/NMDP Leadership Meeting
By Invitation
St. George #106
Friday, February 24, 7:00 am – 8:30 am

Naïve T-Cell Depletion for Prevention of Chronic GVHD (NTCD) Investigators Meeting
By Invitation
Orange Blossom Ballroom
Friday, February 24, 7:00 am – 8:30 am

NMDP Education Consortium Meeting
By Invitation
St. George #112
Saturday, February 25, 7:00 am – 8:30 am

Amy Strelzer Manasevit Research Program Reception
By Invitation
St. George #114
Saturday, February 25, 6:30 pm – 7:45 pm
Special Thanks

Support for the BMT Tandem Meetings has been generously provided by:

**AABB**
8101 Glenbrook Road
Bethesda, MD 20814

**Actinium Pharmaceuticals, Inc.**
275 Madison Avenue, Suite 702
New York, NY 10016

**Alexion Pharmaceuticals**
100 College Street
New Haven, CT 06510

**Astellas Pharma US, Inc.**
One Astellas Way
Northbrook, IL 60062

**Biosafe America Inc.**
1225 North Loop West, Suite 120
Houston, TX 77008

**BloodCenter of Wisconsin**
638 North 18th Street
PO Box 2178
Milwaukee, WI 53201

**BostonSight**
464 Hillside Avenue, Suite 205
Needham, MA 02494

**Celgene Corporation**
86 Morris Avenue
Summit, NJ 07901

**Cerus Corporation**
2550 Stanwell Drive
Concord, CA 94520

**Chimerix, Inc.**
2505 Meridian Parkway
Suite 100
Durham, NC 27713

**City of Hope**
1500 East Duarte Road
Duarte, CA 91010

**Coram CVS Specialty Infusion**
555 17th Street, Suite 1500
Denver, CO 80202

**DKMS**
100 Broadway, 6th Floor
New York, NY 10005

**Feel Good, Inc.**
1460 Gemini Boulevard, #8
Orlando, FL 32837

**Foundation Medicine**
150 Second Street, 1st Floor
Cambridge, MA 02141

**Fresenius Kabi USA, LLC**
3 Corporate Drive
Lake Zurich, IL 60047

**Fresenius Medical Care**
3500 Lacey Road
Downers Grove, IL 60515

**Gilead Sciences, Inc.**
333 Lakeside Drive
Foster City, CA 94404

**HistoGenetics**
300 Executive Boulevard
Ossining, NY 10562

**Immudex**
4031 University Drive, Suite 100
Fairfax, VA 22030

**Incyte Corporation**
1801 Augustine Cut-Off
Wilmington, DE 19803

**Janssen Biotech, Inc.**
1000 U.S. Route 202 South
Raritan, NJ 08869

**Jazz Pharmaceuticals, Inc.**
3180 Porter Drive
Palo Alto, CA 94304

**Karyopharm Therapeutics, Inc.**
85 Wells Avenue, 2nd Floor
Newton, MA 02459

**Kashi Clinical Laboratories**
10101 SW Barbur Boulevard
Portland, OR 97219

**Kite Pharma, Inc.**
2225 Colorade Avenue
Santa Monica, CA 90404
LabCorp
1440 York Court
Burlington, NC 27215

LABS, Inc.
6933 South Revere Parkway
Centennial, CO 80112

Management Science
Associates, Inc.
6565 Penn Avenue
Pittsburgh, PA 15206

Mediware Information
Systems, Inc.
11711 West 79th Street
Lenexa, KS 66214

Memorial Sloan Kettering
Cancer Center
1440 York Avenue
New York, NY 10065

Merck & Company
2000 Galloping Hill Road
Kenilworth, NJ 07033

Millennium: The Takeda
Oncology Co.
40 Landsdowne Street
Cambridge, MA 02139

Miller Pharmacal Group, Inc.
350 Randy Road, Suite 2
Carol Stream, IL 60188

Miltenyi Biotec
Friedrich-Ebert-Strabe 68
Bergisch Gladbach 51429
Germany

NanoEnTek USA, Inc.
5627 Stoneridge Drive
Suite 304
Pleasanton, CA 94588

Nebraska Medicine
988132 Nebraska Medical
Center
Omaha, NE 68198-8132

Novartis Oncology
One Health Plaza
East Hanover, NJ 07936

Omeros Corporation
201 Elliott Avenue West
Seattle, WA 98119

Oncology Nursing
Certification Corporation
125 Enterprise Drive
Pittsburgh, PA 15275

One Lambda, Inc., A Thermo
Fisher Scientific Brand
21001 Kittridge Street
Canoga Park, CA 91303

OriGen Biomedical
7000 Burleson Road, Building D
Austin, TX 78744

OTTR Chronic Care
Solutions, Inc.
10202 F Street
Omaha, NE 68127

Oxford Immunotec
700 Nickerson Road, Suite 200
Marlborough, MA 01752

Pharmacyclics, LLC
999 East Arques Avenue
Sunnyvale, CA 94085

Sandoz Biopharmaceuticals
100 College Road West
Princeton, NJ 08540

Sanofi Genzyme
500 Kendall Street
Cambridge, MA 02142

Sarah Cannon
1100 Charlotte Avenue
Suite 800
Nashville, TN 37203

Seattle Cancer Care Alliance
825 Eastlake Avenue E
Seattle, WA 98109

Seattle Genetics
21823 30th Dr. Southeast
Bothell, WA 98021

Shire
300 Shire Way
Lexington, MA 02421

Stafa Cellular Therapy
2201 Walnut Avenue, #208
Fremont, CA 94538

STEMSOFT Software, Inc.
401-570 West 7th Avenue
Vancouver, BC V5Z 1B3
CANADA
SPECIAL THANKS

stemTrak
35 India Street
Boston, MA 02110

Takeda Oncology
40 Landsdowne Street
Cambridge, MA 02139

TeleResults Corporation
870 Market Street, Suite 556
San Francisco, CA 94123

TerumoBCT
10811 West Collins Avenue
Lakewood, CO 80215

The Children’s Hospital of Philadelphia
34th Street and Civic Center Boulevard
Philadelphia, PA 19026

University of Florida Health Shands Hospital
1600 SW Archer Road
Gainesville, FL 32610

Viracor Eurofins
1001 Northwest Technology Drive
Lee’s Summit, MO 64086

Texas Medical Specialty, Inc.
7777 Forest Lane
Dallas, TX 75230

Additional thanks to the following organizations for their participation in the BMT Tandem Meetings:

BMT InfoNet
1548 Old Skokie Road, Suite 1
Highland Park, IL 60035

Foundation for the Accreditation of Cellular Therapy (FACT)
986065 Nebraska Medical Center
Omaha, NE 68198-6065

National Bone Marrow Transplant Link (nbmtLink)
20411 West 12 Mile Road
Suite 108
Southfield, MI 48076

NMDP/Be The Match
500 North 5th Street
Minneapolis, MN 55413

Oncology Nursing Society
125 Enterprise Drive
Pittsburgh, PA 15275
Florida Exhibition Hall

Florida Hall A

Florida Hall B
Poster Sessions

Florida Hall C
Concurrent Sessions

Florida Hall D
Concurrent Sessions

Florida Hall E
Satellite Symposia, Plenary and Concurrent Sessions

Exhibit Hall F
Exhibits and BMT Tandem Buffet
Convention Center Level 2

Sun and Osceola Ballrooms

Sun Ballroom

Peripherals

A

Sun Foyer

Product Theaters

B

Ad Hoc/Miscellaneous

C

City Hall Lobby

D

Osceola Foyer

Working Committees

A

Peripherals

Osceola Ballroom

B

C

D

Speaker Ready Room
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCME</td>
<td>Accreditation Council for Continuing Medical Education</td>
</tr>
<tr>
<td>ACPE</td>
<td>Accreditation Council for Pharmacy Education</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>AML</td>
<td>Acute Myeloid (Myelogenous) Leukemia</td>
</tr>
<tr>
<td>aGVHD</td>
<td>Acute Graft-Versus-Host Disease</td>
</tr>
<tr>
<td>ALL</td>
<td>Acute Lymphoblastic Leukemia</td>
</tr>
<tr>
<td>ALWP</td>
<td>Acute Leukemia Working Party</td>
</tr>
<tr>
<td>AMA</td>
<td>American Medical Association</td>
</tr>
<tr>
<td>ANCC</td>
<td>American Nurses Credentialing Center</td>
</tr>
<tr>
<td>APP(s)</td>
<td>Advanced Practice Professional(s)</td>
</tr>
<tr>
<td>ASCT</td>
<td>Autologous Stem Cell Transplant</td>
</tr>
<tr>
<td>ASBMT</td>
<td>American Society of Blood and Marrow Transplantation</td>
</tr>
<tr>
<td>ATG</td>
<td>Anti-thymocyte Globulin</td>
</tr>
<tr>
<td>BBMT</td>
<td>Biology of Blood and Marrow Transplantation</td>
</tr>
<tr>
<td>BKV</td>
<td>BK Virus</td>
</tr>
<tr>
<td>BMT</td>
<td>Bone Marrow Transplantation</td>
</tr>
<tr>
<td>BMT CTN</td>
<td>Blood and Marrow Transplant Clinical Trials Network</td>
</tr>
<tr>
<td>CAC</td>
<td>Consumer Advocacy Committee</td>
</tr>
<tr>
<td>CAR</td>
<td>Chimeric Antigen Receptor</td>
</tr>
<tr>
<td>CB</td>
<td>Cord Blood</td>
</tr>
<tr>
<td>CE</td>
<td>Continuing Education</td>
</tr>
<tr>
<td>CEU</td>
<td>Continuing Education Unit</td>
</tr>
<tr>
<td>CIBMTR</td>
<td>Center for International Blood and Marrow Transplant Research</td>
</tr>
<tr>
<td>CLL</td>
<td>Chronic Lymphocytic Leukemia</td>
</tr>
<tr>
<td>CME</td>
<td>Continuing Medical Education</td>
</tr>
<tr>
<td>CMS</td>
<td>Centers for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>CML</td>
<td>Chronic Myeloid (Myelogenous) Leukemia</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>CNE</td>
<td>Continuing Nursing Education</td>
</tr>
<tr>
<td>CNS</td>
<td>Central Nervous System</td>
</tr>
<tr>
<td>COG</td>
<td>Children's Oncology Group</td>
</tr>
<tr>
<td>CPI</td>
<td>Continuous Process Improvement</td>
</tr>
<tr>
<td>CRP/DM</td>
<td>Clinical Research Professionals/Data Management</td>
</tr>
<tr>
<td>CY</td>
<td>Cyclophosphamide</td>
</tr>
<tr>
<td>EBMT</td>
<td>European Group for Blood and Marrow Transplantation</td>
</tr>
<tr>
<td>EBV</td>
<td>Epstein-Barr Virus</td>
</tr>
<tr>
<td>FACT</td>
<td>Foundation for Accreditation of Cellular Therapy</td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practice</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Form</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>GVHD</td>
<td>Graft-Versus-Host Disease</td>
</tr>
<tr>
<td>GVL</td>
<td>Graft-Versus-Leukemia</td>
</tr>
<tr>
<td>HCT</td>
<td>Hematopoietic (Stem) Cell Transplantation</td>
</tr>
<tr>
<td>HHV</td>
<td>Human Herpes Viruses</td>
</tr>
<tr>
<td>HL</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>HLA</td>
<td>Human Leukocyte Antigen</td>
</tr>
<tr>
<td>HLH</td>
<td>Hemophagocytic Lymphohistiocytosis</td>
</tr>
<tr>
<td>I-BFM</td>
<td>International BFM Study Group</td>
</tr>
<tr>
<td>IBMTR</td>
<td>International Bone Marrow Transplant Registry</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>JAK</td>
<td>Janus Kinase</td>
</tr>
<tr>
<td>KIR</td>
<td>Killer Cell Immunoglobulin-like Receptors</td>
</tr>
<tr>
<td>LABMT</td>
<td>Latin America Blood and Marrow Transplantation</td>
</tr>
<tr>
<td>MACRA</td>
<td>Medicare Access and CHIP Reauthorization Act of 2015</td>
</tr>
<tr>
<td>MCW</td>
<td>Medical College of Wisconsin</td>
</tr>
<tr>
<td>MDS</td>
<td>Myelodysplastic Syndrome</td>
</tr>
<tr>
<td>MF</td>
<td>Myelofibrosis</td>
</tr>
<tr>
<td>MIPS</td>
<td>Merit-Based Incentive Payment System</td>
</tr>
<tr>
<td>MMUD</td>
<td>Mismatched Unrelated Donor Transplantation</td>
</tr>
<tr>
<td>MRD</td>
<td>Minimal Residual Disease</td>
</tr>
<tr>
<td>NABP</td>
<td>National Association of Boards of Pharmacy</td>
</tr>
<tr>
<td>NCDB</td>
<td>National Cancer Database</td>
</tr>
<tr>
<td>NHL</td>
<td>Non-Hodgkin Lymphoma</td>
</tr>
<tr>
<td>NK</td>
<td>Natural Killer (Cell)</td>
</tr>
<tr>
<td>NMDP</td>
<td>National Marrow Donor Program</td>
</tr>
<tr>
<td>ONS</td>
<td>Oncology Nursing Society</td>
</tr>
<tr>
<td>PBMTC</td>
<td>Pediatric Blood and Marrow Transplant Consortium</td>
</tr>
<tr>
<td>PBSCT</td>
<td>Peripheral Blood Stem Cells Transplantation</td>
</tr>
<tr>
<td>PCOR</td>
<td>Patient-Centered Outcomes Research</td>
</tr>
<tr>
<td>PCORI</td>
<td>Patient-Centered Outcomes Research Institute</td>
</tr>
<tr>
<td>PDWP</td>
<td>Pediatric Diseases Working Party</td>
</tr>
<tr>
<td>PROMIS</td>
<td>Patient-Reported Outcomes Measurement Information System</td>
</tr>
<tr>
<td>PTCy</td>
<td>Post-Transplantation Cyclophosphamide</td>
</tr>
<tr>
<td>RCI BMT</td>
<td>Resource for Clinical Investigation in Blood and Marrow Transplantation</td>
</tr>
<tr>
<td>RFI</td>
<td>Request for Information</td>
</tr>
<tr>
<td>RITN</td>
<td>Radiation Injury Treatment Network</td>
</tr>
<tr>
<td>SAA</td>
<td>Severe Aplastic Anemia</td>
</tr>
<tr>
<td>SCD</td>
<td>Sickle Cell Disease</td>
</tr>
<tr>
<td>SCT</td>
<td>Stem Cell Transplantation</td>
</tr>
<tr>
<td>SF</td>
<td>Short Form</td>
</tr>
<tr>
<td>SIG</td>
<td>Special Interest Group</td>
</tr>
<tr>
<td>SPEP</td>
<td>Serum Protein Electrophoresis</td>
</tr>
<tr>
<td>TA-GVHD</td>
<td>Transfusion-Associated Graft-Versus-Host Disease</td>
</tr>
</tbody>
</table>
TAM  Transplant-Associated Microangiopathy
TEM  Transverse Electro-Magnetic
TKI  Tyrosine Kinase Inhibitor
TMA  Thrombotic Microangiopathy
TX   Transplant
UPEP Urine Protein Electrophoresis
VOD  Veno-Occlusive Disease
VZV  Varicella-Zoster Virus
WBMT Worldwide Network for Blood and Marrow Transplantation
BMT Tandem Meetings

February 21-25, 2018
Salt Lake City, Utah

Comprehensive Update on Blood and Marrow Transplantation
• Laboratory Research
• Clinical Investigations • Patient Care

Early Registration & Abstract Deadline:
October 3, 2017

Online Registration & Abstract Submission:
www.cibmtr.org or www.asbmt.org
You are invited to **Mambo for Myeloma** at the BMT Tandem Annual Meetings!

Sanofi Genzyme will make a donation of up to $10,000 to support ASBMT and CIBMTR.

Join us at Booth 100/102 to find out more about how you can support.

Follow us on Facebook and Twitter throughout the congress.

#IMambo4Myeloma